{"content":"<li class=\"n-box-item date-title\" data-end=\"1563249599\" data-start=\"1563163200\" data-txt=\"Monday, December 23, 2019\">Monday, July 15, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3477924\" data-ts=\"1563228792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PDVW\" target=\"_blank\">PDVW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477924-pdvwirelessminus-6-on-filing-to-offer-85m-in-stock\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PdvWireless -6% on filing to offer $85M in stock</a></h4><ul>   <li>PdvWireless (NASDAQ:<a href='https://seekingalpha.com/symbol/PDVW' title='pdvWireless, Inc.'>PDVW</a>) -- now rebranded as Anterix -- is <font color=\"red\">6% lower</font> after filing a registration to <a href=\"https://www.sec.gov/Archives/edgar/data/1304492/000119312519194033/d756729d424b5.htm#suprom756729_6\" target=\"_blank\">offer $85M in common stock</a>.</li>    <li>The filing comes via Morgan Stanley, J.P. Morgan, Evercore ISI, B. Riley FBR and Craig-Hallum Group.</li>    <li>Net proceeds of about $79.9M are expected to go toward retuning spectrum by relocating incumbents, and acquiring additional spectrum to qualify for broadband licenses and support broadband use, along with general purposes.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477924\" data-linked=\"PdvWireless -6% on filing to offer $85M in stock\" data-tweet=\"$PDVW $ATEX - PdvWireless -6% on filing to offer $85M in stock https://seekingalpha.com/news/3477924-pdvwirelessminus-6-on-filing-to-offer-85m-in-stock?source=tweet\" data-url=\"https://seekingalpha.com/news/3477924-pdvwirelessminus-6-on-filing-to-offer-85m-in-stock\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477919\" data-ts=\"1563227057\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477919-sqm-jbht-and-arw-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SQM, JBHT and ARW among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/JBHT' title='J.B. Hunt Transport Services, Inc.'>JBHT</a> <font color=\"green\">+6.1%</font>. <a href='https://seekingalpha.com/symbol/HCR' title='Hi-Crush Inc.'>HCR</a> <font color=\"green\">+2.9%</font>. <a href='https://seekingalpha.com/symbol/ARD' title='Ardagh Group S.A.'>ARD</a> <font color=\"green\">+2.7%</font>. <a href='https://seekingalpha.com/symbol/HX' title='Hexindai Inc.'>HX</a> <font color=\"green\">+2.6%</font>. <a href='https://seekingalpha.com/symbol/TEO' title='Telecom Argentina S.A.'>TEO</a> <font color=\"green\">+1.8%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/CBLK' title='Carbon Black, Inc.'>CBLK</a> <font color=\"red\">-4.8%</font>. <a href='https://seekingalpha.com/symbol/ARW' title='Arrow Electronics, Inc.'>ARW</a> <font color=\"red\">-4.2%</font>.<a href='https://seekingalpha.com/symbol/RGEN' title='Repligen Corporation'>RGEN</a> <font color=\"red\">-3.5%</font>. <a href='https://seekingalpha.com/symbol/RMED' title='Ra Medical Systems, Inc.'>RMED</a> <font color=\"red\">-2.6%. </font><a href='https://seekingalpha.com/symbol/SQM' title='Sociedad Química y Minera de Chile S.A.'>SQM</a> <font color=\"red\">-1.0%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477919\" data-linked=\"SQM, JBHT and ARW among after hour movers\" data-tweet=\"$JBHT $HCR $ARD - SQM, JBHT and ARW among after hour movers https://seekingalpha.com/news/3477919-sqm-jbht-and-arw-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477919-sqm-jbht-and-arw-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477913\" data-ts=\"1563226407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTVT\" target=\"_blank\">VTVT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477913-vtv-therapeutics-to-present-alzheimers-conference-sharesplus-8_8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VTv Therapeutics to present at Alzheimer&#39;s conference; shares +8.8%</a></h4><ul>   <li>VTv Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics Inc.'>VTVT</a>) has <font color=\"green\">risen 8.8%</font> postmarket after it <a href=\"https://seekingalpha.com/pr/17571886-vtv-therapeutics-present-2019-alzheimer-s-association-international-conference\" target=\"_blank\">says it will present</a> at this week's Alzheimer's Association International Conference.</li>    <li>The oral presentation will cover data from its phase 3 STEADFAST study and the preceding phase 2B study of azeliragon to \"further support the biological hypothesis for the potential beneficial effects of azeliragon on the ADAS-cog and CDR-sb in patients with mild Alzheimer\u2019s disease and type 2 diabetes.\"</li>    <li>Azeliragon is an orally active small-molecule antagonist of the receptor for advanced glycation endproducts &#40;RAGE&#41;.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477913\" data-linked=\"VTv Therapeutics to present at Alzheimer&#39;s conference; shares +8.8%\" data-tweet=\"$VTVT - VTv Therapeutics to present at Alzheimer&#39;s conference; shares +8.8% https://seekingalpha.com/news/3477913-vtv-therapeutics-to-present-alzheimers-conference-sharesplus-8_8?source=tweet\" data-url=\"https://seekingalpha.com/news/3477913-vtv-therapeutics-to-present-alzheimers-conference-sharesplus-8_8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477899\" data-ts=\"1563224678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABUS\" target=\"_blank\">ABUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477899-arbutus-up-3-after-hours-on-encouraging-data-on-hbv-candidate-abminus-506\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arbutus up 3% after hours on encouraging data on HBV candidate AB-506</a></h4><ul><li>Arbutus Biopharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ABUS' title='Arbutus Biopharma Corporation'>ABUS</a>) perks up <font color=\"green\">3%</font> after hours in reaction to <a href=\"https://seekingalpha.com/pr/17571785-arbutus-announces-preliminary-phase-1a-1b-clinical-trial-results-abminus-506-oral-capsid\" target=\"_blank\">positive data</a> from a Phase 1a/1b clinical trial evaluating HBV capsid inhibitor AB-506 in healthy volunteers and two cohorts with chronic hepatitis B virus &#40;HBV&#41; infection.</li><li>In the healthy subjects, no serious treatment-related adverse events were reported. Liver function test remained normal throughout the 10-day dosing period.</li><li>In the hepatitis B groups, mean HBV DNA decreased 100-fold to ~630-fold (160 mg, 400 mg doses) at day 28 while HBV RNA decreased ~250-fold in both dose cohorts.</li><li>On the safety front, four HBV subjects experienced life-threatening flares in the liver enzyme ALT (biomarker for liver damage) which returned to baseline after treatment was completed or discontinued. Another liver enzyme, AST, spiked to a lesser degree. None met the criteria for induced liver injury since bilirubin and liver synthetic function remained normal.</li><li>Detailed results will be submitted for presentation at a future scientific conference.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477899\" data-linked=\"Arbutus up 3% after hours on encouraging data on HBV candidate AB-506\" data-tweet=\"$ABUS - Arbutus up 3% after hours on encouraging data on HBV candidate AB-506 https://seekingalpha.com/news/3477899-arbutus-up-3-after-hours-on-encouraging-data-on-hbv-candidate-abminus-506?source=tweet\" data-url=\"https://seekingalpha.com/news/3477899-arbutus-up-3-after-hours-on-encouraging-data-on-hbv-candidate-abminus-506\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477893\" data-ts=\"1563224116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAYRY\" target=\"_blank\">BAYRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477893-bayer-spikes-judge-cuts-roundup-punitive-damages-to-20m-from-75m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bayer spikes as judge cuts Roundup punitive damages to $20M from $75M</a></h4><ul><li>Bayer (<a href='https://seekingalpha.com/symbol/BAYRY' title='Bayer Aktiengesellschaft'>OTCPK:BAYRY</a>) popped just before the close to finish <font color=\"green\">+2.9%</font> after a U.S. district judge <a href=\"https://finance.yahoo.com/news/1-u-judge-slashes-roundup-203710064.html\" target=\"_blank\">cut the damages award</a> it had owed a California man who blamed Roundup weedkiller for his cancer to $25.27M from $80.27M.</li><li>Judge Chhabria said he agreed that the evidence supported the $5.27M compensatory damages award and that the jury acted reasonably in awarding punitive damages, but he slashed punitive damages to $20M from $75M, saying it was \"constitutionally impermissible\" to award the higher amount, which was ~15x the size of the compensatory damages award.</li><li>Bayer says the ruling is \"a step in the right direction\" but still plans to appeal the verdict and damages award to the federal appeals court in San Francisco.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477893\" data-linked=\"Bayer spikes as judge cuts Roundup punitive damages to $20M from $75M\" data-tweet=\"$BAYRY - Bayer spikes as judge cuts Roundup punitive damages to $20M from $75M https://seekingalpha.com/news/3477893-bayer-spikes-judge-cuts-roundup-punitive-damages-to-20m-from-75m?source=tweet\" data-url=\"https://seekingalpha.com/news/3477893-bayer-spikes-judge-cuts-roundup-punitive-damages-to-20m-from-75m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477890\" data-ts=\"1563223630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477890-interpace-up-9-after-hours-on-cancer-genetics-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace up 9% after hours on Cancer Genetics deal</a></h4><ul><li>Interpace Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a>) has <a href=\"https://seekingalpha.com/pr/17571794-interpace-diagnostics-acquires-cancer-genetics-biopharma-services-business-supported\" target=\"_blank\">acquired </a>Cancer Genetics' (NASDAQ:<a href='https://seekingalpha.com/symbol/CGIX' title='Cancer Genetics, Inc.'>CGIX</a>) Biopharma Services business for ~$23.5M subject to adjustments. The business generated ~$15M in revenue in 2018.</li><li>Concurrently, private equity shop Ampersand Capital Partners has agreed to invest $27M in Interpace in two tranches of newly issued convertible preferred stock.</li><li>IDXG is up <font color=\"green\">9%</font> after hours while CGIX is up <font color=\"green\">59%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477890\" data-linked=\"Interpace up 9% after hours on Cancer Genetics deal\" data-tweet=\"$IDXG $CGIX - Interpace up 9% after hours on Cancer Genetics deal https://seekingalpha.com/news/3477890-interpace-up-9-after-hours-on-cancer-genetics-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3477890-interpace-up-9-after-hours-on-cancer-genetics-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477867\" data-ts=\"1563222537\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ECOR\" target=\"_blank\">ECOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477867-electrocore-files-for-50m-mixed-shelf-shares-down-2-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ElectroCore files for $50M mixed shelf; shares down 2% after hours</a></h4><ul><li>ElectroCore (NASDAQ:<a href='https://seekingalpha.com/symbol/ECOR' title='electroCore, Inc.'>ECOR</a>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1560258/000119312519193990/d776534ds3.htm\" target=\"_blank\">prospectus </a>for a $50M mixed shelf offering.</li><li>Shares are down <font color=\"red\">2%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477867\" data-linked=\"ElectroCore files for $50M mixed shelf; shares down 2% after hours\" data-tweet=\"$ECOR - ElectroCore files for $50M mixed shelf; shares down 2% after hours https://seekingalpha.com/news/3477867-electrocore-files-for-50m-mixed-shelf-shares-down-2-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3477867-electrocore-files-for-50m-mixed-shelf-shares-down-2-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477864\" data-ts=\"1563222390\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EPRT\" target=\"_blank\">EPRT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477864-essential-propertiesminus-4_1-after-secondary-offering-announced\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Essential Properties -4.1% after secondary offering announced</a></h4><ul><li>Essential Properties Realty Trust (NYSE:<a href='https://seekingalpha.com/symbol/EPRT' title='Essential Properties Realty Trust, Inc.'>EPRT</a>) <font color=\"red\">slumps 4.1%</font> in after-hours trading after selling stockholders affiliated with Eldridge Industries <a href=\"https://seekingalpha.com/pr/17571764-essential-properties-realty-trust-inc-announces-secondary-offering-common-stock\" target=\"_blank\">start a secondary public offering</a> of 17.25M EPRT shares.</li><li>Selling holders expect to grant greenshoe option for up to an additional 2,587,500 shares of common stock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477864\" data-linked=\"Essential Properties -4.1% after secondary offering announced\" data-tweet=\"$EPRT - Essential Properties -4.1% after secondary offering announced https://seekingalpha.com/news/3477864-essential-propertiesminus-4_1-after-secondary-offering-announced?source=tweet\" data-url=\"https://seekingalpha.com/news/3477864-essential-propertiesminus-4_1-after-secondary-offering-announced\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477862\" data-ts=\"1563222326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARW\" target=\"_blank\">ARW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477862-arrowminus-6-on-prelim-q2-unit-wind-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arrow -6% on prelim. Q2, unit wind down</a></h4><ul><li>Arrow Electronics (NYSE:<a href='https://seekingalpha.com/symbol/ARW' title='Arrow Electronics, Inc.'>ARW</a>) <a href=\"https://seekingalpha.com/pr/17571778-arrow-electronics-provides-business-update\" target=\"_blank\">reports</a> preliminary Q2 results with sales of $5.3B, which includes $5.25B for global components and $2.05B for global enterprise computing solutions. EPS is expected between $1.50 to $1.62.</li><li>Arrow plans to wind down its personal computer and mobility asset disposition business in the U.S. and most other countries. The business reported as part of the global components arm. The company expects to take $115M in charges primarily in Q2 and to complete the shuttering by the end of 2019.</li><li>Key management quote: \"While we are disappointed that our anticipated results for the second quarter are lower than we had initially expected due to deteriorating demand conditions in the global components business, we remain confident in our long-term strategy and our ability to generate strong cash flow.\"</li><li>Arrow shares are <font color=\"red\">down 6.3%</font> after hours to $64.56.</li><li>Post updated to correct EPS forecast.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477862\" data-linked=\"Arrow -6% on prelim. Q2, unit wind down\" data-tweet=\"$ARW - Arrow -6% on prelim. Q2, unit wind down https://seekingalpha.com/news/3477862-arrowminus-6-on-prelim-q2-unit-wind-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3477862-arrowminus-6-on-prelim-q2-unit-wind-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477860\" data-ts=\"1563222284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNMX\" target=\"_blank\">GNMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477860-aevi-genomic-med-up-23-after-hours-on-astellas-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aevi Genomic Med up 23% after hours on Astellas deal</a></h4><ul><li>Nano cap Aevi Genomic Medicine (NASDAQ:<a href='https://seekingalpha.com/symbol/GNMX' title='Aevi Genomic Medicine, Inc.'>GNMX</a>) is up <font color=\"green\">23%</font> after hours on the heels of its exclusive in-license <a href=\"https://seekingalpha.com/pr/17571767-aevi-genomic-medicine-enters-worldwide-license-agreement-astellas-develop-commercialize-novel\" target=\"_blank\">agreement </a>with Astellas Pharma (<a href='https://seekingalpha.com/symbol/ALPMF' title='Astellas Pharma Inc.'>OTCPK:ALPMF</a>) unit OSI Pharmaceuticals securing global development and commercialization rights to ASP7486 (formerly OSI-027).</li><li>Aevi will initially develop the mTORC1/2 inhibitor to treat rare inherited lymphatic malformations such as generalized lymphatic anomaly, Kaposiform lymphangiomatosis and Gorham-Stoudt disease.</li><li>Under the terms of the deal, Aevi will pay Astellas $500K upfront, development and regulatory milestones and tiered single-digit royalties on net sales. Aevi will be responsible for all clinical development, manufacturing and commercialization activities and costs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477860\" data-linked=\"Aevi Genomic Med up 23% after hours on Astellas deal\" data-tweet=\"$GNMX $ALPMF $ALPMY - Aevi Genomic Med up 23% after hours on Astellas deal https://seekingalpha.com/news/3477860-aevi-genomic-med-up-23-after-hours-on-astellas-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3477860-aevi-genomic-med-up-23-after-hours-on-astellas-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477846\" data-ts=\"1563221326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RGEN\" target=\"_blank\">RGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477846-repligen-launches-350m-capital-raise-shares-down-3-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Repligen launches $350M capital raise; shares down 3% after hours</a></h4><ul><li>Repligen (NASDAQ:<a href='https://seekingalpha.com/symbol/RGEN' title='Repligen Corporation'>RGEN</a>) slips <font color=\"red\">3%</font> after hours in reaction to its $100M <a href=\"https://seekingalpha.com/pr/17571762-repligen-corporation-announces-proposed-public-offerings-100-million-common-stock-250-million\" target=\"_blank\">public offering</a> of common stock and $250M public offering of convertible senior notes due 2024.</li><li>Prices, volumes and terms have yet to be announced.</li><li>Net proceeds will fund the redemption of its outstanding 2.125% convertible senior notes due 2021 (~$115M) and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477846\" data-linked=\"Repligen launches $350M capital raise; shares down 3% after hours\" data-tweet=\"$RGEN - Repligen launches $350M capital raise; shares down 3% after hours https://seekingalpha.com/news/3477846-repligen-launches-350m-capital-raise-shares-down-3-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3477846-repligen-launches-350m-capital-raise-shares-down-3-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477840\" data-ts=\"1563220651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SEE\" target=\"_blank\">SEE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477840-sealed-air-downgraded-keybanc-on-demand-weakness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sealed Air downgraded at KeyBanc on demand weakness</a></h4><ul><li>Sealed Air (<a href='https://seekingalpha.com/symbol/SEE' title='Sealed Air Corporation'>SEE</a> <font color='red'>-2.3%</font>) slips as KeyBanc analyst Adam Josephson <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/07/14073875/keybanc-downgrades-sealed-air-on-demand-weakness-other-risks\" target=\"_blank\">downgrades</a> shares to Underweight from Sector Weight with a $39 price target, citing concerns about the company's weak volume trends, levered balance sheet, the recent termination of its CFO and an ongoing SEC investigation.</li><li>Josephson also says a restructuring program of the magnitude initiated by SEE typically is difficult to execute and often not very successful, noting the company's cash restructuring payments had exceeded pre-tax restructuring savings since 2013.</li><li>SEE recorded a 1.4% decline in its organic volumes during Q1 due to soft demand in its Product Care segment, which had experienced volume declines for the past three quarters and could continue in Q2 given the weakening global economy, Josephson says.</li><li>SEE's average <a href=\"https://seekingalpha.com/symbol/SEE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, its <a href=\"https://seekingalpha.com/symbol/SEE/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating </a>is Neutral and its <a href=\"https://seekingalpha.com/symbol/SEE/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bullish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477840\" data-linked=\"Sealed Air downgraded at KeyBanc on demand weakness\" data-tweet=\"$SEE - Sealed Air downgraded at KeyBanc on demand weakness https://seekingalpha.com/news/3477840-sealed-air-downgraded-keybanc-on-demand-weakness?source=tweet\" data-url=\"https://seekingalpha.com/news/3477840-sealed-air-downgraded-keybanc-on-demand-weakness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477839\" data-ts=\"1563220433\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVN\" target=\"_blank\">FIVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477839-five9minus-9-on-another-reported-exec-departure\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five9 -9% on another reported exec departure</a></h4><ul><li>Stephens analyst Dmitry Netis cites sources saying Five9 (NASDAQ:<a href='https://seekingalpha.com/symbol/FIVN' title='Five9, Inc.'>FIVN</a>) EVP of Global Sales, Jim Nystrom, is no longer with the company.</li><li>Netis noted in early July that FIVN has lost five to six enterprise execs, and all departed to work for competitors.</li><li>Stephens has an Equal Weight rating and $53 price target on Five9. The company has a Neutral <a href=\"https://seekingalpha.com/symbol/FIVN/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li><li>Five9 shares are <font color=\"red\">down 9.2%</font> to $48.61.</li><li>Related: Earlier today, FIVN <a href=\"https://seekingalpha.com/news/3477820-five9-hires-former-fb-messenger-exec\" target=\"_blank\">announced</a> hiring Facebook vet Anand Chandrasekaran as the new EVP of Product Management.</li><li>Post updated to clarify second bullet.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477839\" data-linked=\"Five9 -9% on another reported exec departure\" data-tweet=\"$FIVN - Five9 -9% on another reported exec departure https://seekingalpha.com/news/3477839-five9minus-9-on-another-reported-exec-departure?source=tweet\" data-url=\"https://seekingalpha.com/news/3477839-five9minus-9-on-another-reported-exec-departure\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477835\" data-ts=\"1563219324\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GEO\" target=\"_blank\">GEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477835-geo-group-corecivic-fall-after-fifth-third-turns-away-from-private-prison-firms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GEO Group, CoreCivic fall after Fifth Third turns away from private prison firms</a></h4><ul><li>GEO Group (<a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a> <font color=\"red\">-1%</font>)<font color=\"red\"> fell as much as 2.4%</font> and CoreCivic (<a href='https://seekingalpha.com/symbol/CXW' title='CoreCivic, Inc.'>CXW</a> <font color=\"red\">-1.6%</font>) slid as much as<font color=\"red\"> 3.1%</font> after Bloomberg reports that Fifth Third Bancorp (<a href='https://seekingalpha.com/symbol/FITB' title='Fifth Third Bancorp'>FITB</a> <font color=\"red\">-1.5%</font>) <a href=\"https://www.bloomberg.com/news/articles/2019-07-15/fifth-third-to-halt-future-financing-to-private-prison-firms\" target=\"_blank\">won't provide future financing </a>to companies that manage private prisons and immigration holding centers.</li><li>\u201cWe will honor the existing credit and loan commitments currently on our books, but we do not intend to enter any new financing arrangements with these companies,\" Fifth Third said in a statement.</li><li>Just yesterday, French bank BNP Paribase said it will no longer finance U.S. private prison operators, following in the steps of JPMorgan Chase, Bank of America, Wells Fargo, and SunTrust Banks, which have taken similar steps.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477835\" data-linked=\"GEO Group, CoreCivic fall after Fifth Third turns away from private prison firms\" data-tweet=\"$GEO $CXW $FITB - GEO Group, CoreCivic fall after Fifth Third turns away from private prison firms https://seekingalpha.com/news/3477835-geo-group-corecivic-fall-after-fifth-third-turns-away-from-private-prison-firms?source=tweet\" data-url=\"https://seekingalpha.com/news/3477835-geo-group-corecivic-fall-after-fifth-third-turns-away-from-private-prison-firms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>105&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477832\" data-ts=\"1563218809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IP\" target=\"_blank\">IP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477832-international-paper-packaging-corp-westrock-all-cut-keybanc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">International Paper, Packaging Corp., WestRock all cut at KeyBanc</a></h4><ul><li>Paper companies International Paper (<a href='https://seekingalpha.com/symbol/IP' title='International Paper Company'>IP</a> <font color='red'>-1.4%</font>), Packaging Corp. of America (<a href='https://seekingalpha.com/symbol/PKG' title='Packaging Corporation of America'>PKG</a> <font color='red'>-2.4%</font>) and WestRock (<a href='https://seekingalpha.com/symbol/WRK' title='WestRock Company'>WRK</a> <font color='red'>-2.8%</font>) tumble after KeyBanc analyst Adam Josephson <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/19/07/14074171/paper-cuts-keybanc-downgrades-international-paper-westrock-packaging-corp-of-americ\" target=\"_blank\">turns bearish</a> amid deteriorating fundamentals in containerboard, pulp and uncoated freesheet paper.</li><li>Although shares of the three companies have underperformed over the past year, Josephson says paper industry prices seem to be on a downtrend following years of market strength, likely prompting further downside to KeyBanc's estimates for 2020.</li><li>Adding that the firm's 2020 estimates are based on margins no lower than historical averages, KeyBanc believes the sector stocks \"will do no better than perform in line with the sector over the next 9-12 months, and in fact are more likely to underperform.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3477832\" data-linked=\"International Paper, Packaging Corp., WestRock all cut at KeyBanc\" data-tweet=\"$IP $PKG $WRK - International Paper, Packaging Corp., WestRock all cut at KeyBanc https://seekingalpha.com/news/3477832-international-paper-packaging-corp-westrock-all-cut-keybanc?source=tweet\" data-url=\"https://seekingalpha.com/news/3477832-international-paper-packaging-corp-westrock-all-cut-keybanc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477828\" data-ts=\"1563217205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477828-microcaps-mostly-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among tech movers</a></h4><ul><li><strong>Gainers: </strong>Perion Network (NASDAQ:<a href='https://seekingalpha.com/symbol/PERI' title='Perion Network Ltd.'>PERI</a>) <font color=\"green\">+12%</font>. AGM Group Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AGMH' title='AGM Group Holdings Inc.'>AGMH</a>) <font color=\"green\">+11%</font>. B Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/BCOM' title='B Communications Ltd'>BCOM</a>) <font color=\"green\">+10%</font>. TuanChe Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"green\">+9%</font>. Creative Realities (NASDAQ:<a href='https://seekingalpha.com/symbol/CREX' title='Creative Realities, Inc.'>CREX</a>) <font color=\"green\">+8%</font>.</li> <li><strong>Losers: </strong>SCWorx (NASDAQ:<a href='https://seekingalpha.com/symbol/WORX' title='SCWorx Corp.'>WORX</a>) <font color=\"red\">-19%</font>. Symantec Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>)<font color=\"red\">-12%</font>. Vislink Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/VISL' title='Vislink Technologies, Inc.'>VISL</a>) <font color=\"red\">-11%</font>. Technical Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/TCCO' title='Technical Communications Corporation'>TCCO</a>) <font color=\"red\">-10%</font>. So-Young International (NASDAQ:<a href='https://seekingalpha.com/symbol/SY' title='So-Young International Inc.'>SY</a>) <font color=\"red\">-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477828\" data-linked=\"Microcaps mostly among tech movers\" data-tweet=\"$PERI $AGMH $BCOM - Microcaps mostly among tech movers https://seekingalpha.com/news/3477828-microcaps-mostly-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477828-microcaps-mostly-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477827\" data-ts=\"1563217012\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CDEV\" target=\"_blank\">CDEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477827-centennial-resource-gas-focused-e-and-ps-downgraded-jefferies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Centennial Resource, other gas-focused E&amp;Ps downgraded at Jefferies</a></h4><ul><li>Centennial Resource Development (<a href='https://seekingalpha.com/symbol/CDEV' title='Centennial Resource Development, Inc.'>CDEV</a> <font color='red'>-8.3%</font>) plunges after Jefferies analyst Mark Lear <a href=\"https://thefly.com/thestreet/realmoney/index.php/CDEV;CPE;CRZO;GPOR;RRC;EOG;FANG;PE;PXDid2932825/CDEV;CPE;CRZO;GPOR;RRC;EOG;FANG;PE;PXD-Jefferies-downgrades-five-in-Exploration--Production-space-ahead-of-results\" target=\"_blank\">downgrades</a> shares to Hold from Buy to reflect the firm's reduced oil and natural gas price forecast.</li><li>Lear anticipates \"another messy quarter\" across the E&amp;P sector driven by weak natural gas liquids and Waha natural gas pricing, \"left in the dust by crude, and it feels to us the market doesn't want, or more importantly need, the crude supply that the U.S. onshore can deliver.\"</li><li>The firm also downgrades Callon Petroleum (<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Company'>CPE</a> <font color='red'>-15.7%</font>), Carrizo Oil &amp; Gas (<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a> <font color='green'>+1.9%</font>), Gulfport Energy (<a href='https://seekingalpha.com/symbol/GPOR' title='Gulfport Energy Corporation'>GPOR</a> <font color='red'>-1.6%</font>) and Range Resources (<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a> <font color='red'>-4.3%</font>) but thinks EOG Resources (<a href='https://seekingalpha.com/symbol/EOG' title='EOG Resources, Inc.'>EOG</a> <font color='red'>-2.3%</font>), Diamondback Energy (<a href='https://seekingalpha.com/symbol/FANG' title='Diamondback Energy, Inc.'>FANG</a> <font color='red'>-3.6%</font>), Parsley Energy (<a href='https://seekingalpha.com/symbol/PE' title='Parsley Energy, Inc.'>PE</a> <font color='red'>-4.8%</font>) and Pioneer Natural Resources (<a href='https://seekingalpha.com/symbol/PXD' title='Pioneer Natural Resources Company'>PXD</a> <font color='red'>-2.4%</font>) are set up well into the quarter.</li><li>SunTrust analysts downgraded CDEV to Hold from Buy <a href=\"https://thefly.com/thestreet/realmoney/index.php/PXD;CDEV;SNDE;OASid2930122/PXD;CDEV;SNDE;OAS-SunTrust-cuts-Pioneer-Natural-Oasis-Petroleum-Centennial-and-Sundance-Energy\" target=\"_blank\">last week</a>, as stronger U.S. production and more moderate demand domestically and in China drives a forecast 5% reduction in their crude oil price assumption in 2019-21.</li><li>CDEV's average <a href=\"https://seekingalpha.com/symbol/CDEV/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, while its <a href=\"https://seekingalpha.com/symbol/CDEV/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Neutral and its <a href=\"https://seekingalpha.com/symbol/CDEV/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477827\" data-linked=\"Centennial Resource, other gas-focused E&amp;Ps downgraded at Jefferies\" data-tweet=\"$CDEV $CPE $CRZO - Centennial Resource, other gas-focused E&amp;Ps downgraded at Jefferies https://seekingalpha.com/news/3477827-centennial-resource-gas-focused-e-and-ps-downgraded-jefferies?source=tweet\" data-url=\"https://seekingalpha.com/news/3477827-centennial-resource-gas-focused-e-and-ps-downgraded-jefferies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477825\" data-ts=\"1563216293\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYMC\" target=\"_blank\">SYMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477825-broadcom-still-interested-in-symc-purchase-ft\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Broadcom still interested in SYMC purchase - FT</a></h4><ul><li>Symantec (<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a> <font color='red'>-12.5%</font>) shares pare some of the morning losses after FT reports Broadcom (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a> <font color='green'>+1.3%</font>) still wants to make a deal.</li><li>Sources say the talks could resume if the sides iron out the differences on valuation. Banks who agreed to finance the transaction are on standby.</li><li>Earlier today, CNBC and Bloomberg <a href=\"https://seekingalpha.com/news/3477679-symantec-minus-17-percent-broadcom-talks-cease-update\" target=\"_blank\">broke the news</a> that the deal talks had ended after Symantec wanted $28/share, and Broadcom allegedly lowered its offer after due diligence.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477825\" data-linked=\"Broadcom still interested in SYMC purchase - FT\" data-tweet=\"$SYMC $NLOK $AVGO - Broadcom still interested in SYMC purchase - FT https://seekingalpha.com/news/3477825-broadcom-still-interested-in-symc-purchase-ft?source=tweet\" data-url=\"https://seekingalpha.com/news/3477825-broadcom-still-interested-in-symc-purchase-ft\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477820\" data-ts=\"1563215393\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIVN\" target=\"_blank\">FIVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477820-five9-hires-former-fb-messenger-exec\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Five9 hires former FB Messenger exec</a></h4><ul><li>Five9 (<a href='https://seekingalpha.com/symbol/FIVN' title='Five9, Inc.'>FIVN</a> <font color='red'>-2.2%</font>) <a href=\"https://seekingalpha.com/pr/17571438-five9-expands-leadership-team-tapping-anand-chandrasekaran-executive-vice-president-product\" target=\"_blank\">appoints</a> Anand Chandrasekaran as the new EVP of Product Management.</li><li>Chandrasekaran previously worked at Facebook as the director of platform and product partnerships, and he helped develop Messenger.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477820\" data-linked=\"Five9 hires former FB Messenger exec\" data-tweet=\"$FIVN - Five9 hires former FB Messenger exec https://seekingalpha.com/news/3477820-five9-hires-former-fb-messenger-exec?source=tweet\" data-url=\"https://seekingalpha.com/news/3477820-five9-hires-former-fb-messenger-exec\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:29 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477815\" data-ts=\"1563214791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HI\" target=\"_blank\">HI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477815-hillenbrand-bounces-after-acquisition-induced-selloff-da-davidson-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hillenbrand bounces after acquisition-induced selloff; DA Davidson upgrades</a></h4><ul><li>Hillenbrand (<a href='https://seekingalpha.com/symbol/HI' title='Hillenbrand, Inc.'>HI</a> <font color='green'>+6.4%</font>) shoots higher after DA Davidson <a href=\"https://thefly.com/thestreet/realmoney/index.php/HIid2932732/HI-Hillenbrand-upgraded-to-Buy-from-Neutral-at-DA-Davidson\" target=\"_blank\">upgrades shares to Buy</a> from Neutral, as analyst Matt Summerville says he is positive on HI's <a href=\"https://seekingalpha.com/news/3477363-hillenbrand-acquire-milacron-2b\" target=\"_blank\">$2B acquisition of Milacron</a> and last Friday's 13% plunge following the announcement was overdone.</li><li>The analyst says the deal as \"transformational\" toward HI becoming a more diversified global enterprise and he sees a \"significant cash accretion potential\" from the transaction.</li><li>HI's average <a href=\"https://seekingalpha.com/symbol/HI/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Outperform, its <a href=\"https://seekingalpha.com/symbol/HI/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> is Neutral, and its <a href=\"https://seekingalpha.com/symbol/HI/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Very Bearish.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477815\" data-linked=\"Hillenbrand bounces after acquisition-induced selloff; DA Davidson upgrades\" data-tweet=\"$HI - Hillenbrand bounces after acquisition-induced selloff; DA Davidson upgrades https://seekingalpha.com/news/3477815-hillenbrand-bounces-after-acquisition-induced-selloff-da-davidson-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3477815-hillenbrand-bounces-after-acquisition-induced-selloff-da-davidson-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477809\" data-ts=\"1563213650\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477809-camber-energy-and-golden-star-resources-among-energy-materials-gainers-callon-petroleum-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Camber Energy and Golden Star Resources among Energy/Materials gainers; Callon Petroleum and Chaparral Energy among losers</a></h4><ul><li><b>Gainers: </b>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+12%</font>. Golden Star Resources (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSS' title='Golden Star Resources Ltd.'>GSS</a>) <font color=\"green\">+10%</font>. Silvercorp Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/SVM' title='Silvercorp Metals Inc.'>SVM</a>) <font color=\"green\">+6%</font>. Endeavour Silver (NYSE:<a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Callon Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Company'>CPE</a>) <font color=\"red\">-15%</font>. Chaparral Energy (NYSE:<a href='https://seekingalpha.com/symbol/CHAP' title='Chaparral Energy, Inc.'>CHAP</a>) <font color=\"red\">-10%</font>. Superior Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/SPN' title='Superior Energy Services, Inc.'>SPN</a>) <font color=\"red\">-9%</font>. Centennial Resource Development (NASDAQ:<a href='https://seekingalpha.com/symbol/CDEV' title='Centennial Resource Development, Inc.'>CDEV</a>) <font color=\"red\">-9%</font>. Hi-Crush (NYSE:<a href='https://seekingalpha.com/symbol/HCR' title='Hi-Crush Inc.'>HCR</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477809\" data-linked=\"Camber Energy and Golden Star Resources among Energy/Materials gainers; Callon Petroleum and Chaparral Energy among losers\" data-tweet=\"$CEI $GSS $SVM - Camber Energy and Golden Star Resources among Energy/Materials gainers; Callon Petroleum and Chaparral Energy among losers https://seekingalpha.com/news/3477809-camber-energy-and-golden-star-resources-among-energy-materials-gainers-callon-petroleum-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3477809-camber-energy-and-golden-star-resources-among-energy-materials-gainers-callon-petroleum-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477805\" data-ts=\"1563211374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477805-rapid7-dropbox-facing-easier-earnings-comps-nomura\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rapid7, Dropbox facing easier earnings comps - Nomura</a></h4><ul><li>Nomura analyst Christopher Eberle says the YTD software stock rally raised expectations and created challenges for investors to navigate during the approaching earnings season.</li><li>Eberle says Rapid7 (<a href='https://seekingalpha.com/symbol/RPD' title='Rapid7, Inc.'>RPD</a> <font color='green'>+1.1%</font>) and Dropbox (<a href='https://seekingalpha.com/symbol/DBX' title='Dropbox, Inc.'>DBX</a> <font color='green'>+0.9%</font>) have some of the easiest comps in the sector, while Salesforce (<a href='https://seekingalpha.com/symbol/CRM' title='salesforce.com, inc.'>CRM</a> <font color='green'>+0.5%</font>) and Tenable (<a href='https://seekingalpha.com/symbol/TENB' title='Tenable Holdings, Inc.'>TENB</a> <font color='red'>-0.1%</font>) are among those facing tougher comparisons.</li><li>IBM kicks off the tech earnings season with its report on Wednesday, and Microsoft will follow on Thursday.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477805\" data-linked=\"Rapid7, Dropbox facing easier earnings comps - Nomura\" data-tweet=\"$RPD $DBX $CRM - Rapid7, Dropbox facing easier earnings comps - Nomura https://seekingalpha.com/news/3477805-rapid7-dropbox-facing-easier-earnings-comps-nomura?source=tweet\" data-url=\"https://seekingalpha.com/news/3477805-rapid7-dropbox-facing-easier-earnings-comps-nomura\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477802\" data-ts=\"1563210855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRVL\" target=\"_blank\">MRVL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477802-marvellplus-2_8-new-bull-praises-next-phase\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Marvell +2.8% as new bull praises next phase</a></h4><ul><li>William Blair starts Marvell (NASDAQ:<a href='https://seekingalpha.com/symbol/MRVL' title='Marvell Technology Group Ltd.'>MRVL</a>) at Outperform with analyst Alessandra Vecchi predicting the company's \"next phase\" of growth is just beginning.</li><li>Vecchi cites expansions into a number of growth verticals, including 5G, auto, and ARM-based server builds.</li><li>The firm thinks MRVL could surpass its long-term target of 6% to 8% revenue growth, and still sees the runway for margin expansion. Gross margin could exceed 66% and operating margin could reach 35% by the end of FY22 or early FY23.</li><li>MRVL shares are <font color=\"green\">up 2.8%</font> to $26.10.</li><li>Marvell has an Outperform <a href=\"https://seekingalpha.com/symbol/MRVL/ratings/sell-side-ratings\" target=\"_blank\">average Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477802\" data-linked=\"Marvell +2.8% as new bull praises next phase\" data-tweet=\"$MRVL - Marvell +2.8% as new bull praises next phase https://seekingalpha.com/news/3477802-marvellplus-2_8-new-bull-praises-next-phase?source=tweet\" data-url=\"https://seekingalpha.com/news/3477802-marvellplus-2_8-new-bull-praises-next-phase\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477798\" data-ts=\"1563210033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477798-american-electric-technologies-and-hillenbrand-among-industrial-gainers-circor-international\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Electric Technologies and Hillenbrand among Industrial gainers; CIRCOR International and NN among losers</a></h4><ul><li><b>Gainers: </b>American Electric Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AETI' title='American Electric Technologies, Inc'>AETI</a>) <font color=\"green\">+21%</font>. Hillenbrand (NYSE:<a href='https://seekingalpha.com/symbol/HI' title='Hillenbrand, Inc.'>HI</a>) <font color=\"green\">+7%</font>. Hebron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/HEBT' title='Hebron Technology Co., Ltd.'>HEBT</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>CIRCOR International (NYSE:<a href='https://seekingalpha.com/symbol/CIR' title='CIRCOR International, Inc.'>CIR</a>) <font color=\"red\">-13%</font>. NN (NASDAQ:<a href='https://seekingalpha.com/symbol/NNBR' title='NN, Inc.'>NNBR</a>) <font color=\"red\">-7%</font>. Great Lakes Dredge &amp; Dock (NASDAQ:<a href='https://seekingalpha.com/symbol/GLDD' title='Great Lakes Dredge & Dock Corporation'>GLDD</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477798\" data-linked=\"American Electric Technologies and Hillenbrand among Industrial gainers; CIRCOR International and NN among losers\" data-tweet=\"$SLNG $HI $HEBT - American Electric Technologies and Hillenbrand among Industrial gainers; CIRCOR International and NN among losers https://seekingalpha.com/news/3477798-american-electric-technologies-and-hillenbrand-among-industrial-gainers-circor-international?source=tweet\" data-url=\"https://seekingalpha.com/news/3477798-american-electric-technologies-and-hillenbrand-among-industrial-gainers-circor-international\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477797\" data-ts=\"1563209930\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477797-ashford-and-power-reit-among-financial-gainers-jupai-holdings-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ashford and Power REIT among financial gainers, Jupai Holdings leads losers</a></h4><ul><li><b>Gainers:</b> Carolina Trust BancShares (NASDAQ:<a href='https://seekingalpha.com/symbol/CART' title='Carolina Trust BancShares, Inc.'>CART</a>) <font color=\"green\">+31%</font>. Ashford (NYSEMKT:<a href='https://seekingalpha.com/symbol/AINC' title='Ashford Inc.'>AINC</a>) <font color=\"green\">+11%</font>. Power REIT (NYSEMKT:<a href='https://seekingalpha.com/symbol/PW' title='Power REIT'>PW</a>) <font color=\"green\">+8%.</font></li><li><b>Losers:</b> Jupai Holdings (NYSE:<a href='https://seekingalpha.com/symbol/JP' title='Jupai Holdings Limited'>JP</a>) <font color=\"red\">-9%</font>. Conifer Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CNFR' title='Conifer Holdings, Inc.'>CNFR</a>) <font color=\"red\">-8%</font>. Mesabi Trust (NYSE:<a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a>) <font color=\"red\">-6%</font>. Senmiao Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/AIHS' title='Senmiao Technology Limited'>AIHS</a>) <font color=\"red\">-5%</font>. Yintech Investment Holdings <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477797\" data-linked=\"Ashford and Power REIT among financial gainers, Jupai Holdings leads losers\" data-tweet=\"$CART $AINC $PW - Ashford and Power REIT among financial gainers, Jupai Holdings leads losers https://seekingalpha.com/news/3477797-ashford-and-power-reit-among-financial-gainers-jupai-holdings-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477797-ashford-and-power-reit-among-financial-gainers-jupai-holdings-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477790\" data-ts=\"1563209162\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477790-jpmorgan-sees-unit-revenue-upside-spirit-airlines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JPMorgan sees unit revenue upside at Spirit Airlines</a></h4><ul> <li>JPMorgan sizes up Spirit Airlines (<a href='https://seekingalpha.com/symbol/SAVE' title='Spirit Airlines, Inc.'>SAVE</a> <font color=\"red\">-0.5%</font>) following the airline's traffic report and guidance update.</li> <li>\"We believe that ~15% ASM growth in 2019-20 will help Spirit generate an even stronger unit revenue trajectory, particularly as Spirit has increased the number of markets where it has at least 20 daily departures and therefore enhanced density,\" writes analyst Jamie Baker.</li> <li>\"While we believed that Basic Economy would serve as a significant earnings headwind for Spirit, the company has deftly tweaked its business model to reduce exposure to the most competitive markets,\" he adds.</li> <li>JPMorgan has an Overweight rating on SAVE and price target of $72 (10X the 2020 EPS estimate) vs. the <a href=\"https://seekingalpha.com/symbol/SAVE/ratings/sell-side-ratings\" target=\"_blank\">sell-side average PT</a> of $69.07.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477790\" data-linked=\"JPMorgan sees unit revenue upside at Spirit Airlines\" data-tweet=\"$SAVE - JPMorgan sees unit revenue upside at Spirit Airlines https://seekingalpha.com/news/3477790-jpmorgan-sees-unit-revenue-upside-spirit-airlines?source=tweet\" data-url=\"https://seekingalpha.com/news/3477790-jpmorgan-sees-unit-revenue-upside-spirit-airlines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477788\" data-ts=\"1563208924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVTR\" target=\"_blank\">NVTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477788-nuvectra-files-for-100m-mixed-shelf\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nuvectra files for $100M mixed shelf</a></h4><ul><li>Nuvectra (<a href='https://seekingalpha.com/symbol/NVTR' title='Nuvectra Corporation'>NVTR</a> <font color=\"red\">-1.5%</font>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1648893/000143774919013925/nvtr20190710_s3.htm\" target=\"_blank\">prospectus </a>for a $100M mixed shelf offering.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477788\" data-linked=\"Nuvectra files for $100M mixed shelf\" data-tweet=\"$NVTR - Nuvectra files for $100M mixed shelf https://seekingalpha.com/news/3477788-nuvectra-files-for-100m-mixed-shelf?source=tweet\" data-url=\"https://seekingalpha.com/news/3477788-nuvectra-files-for-100m-mixed-shelf\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477785\" data-ts=\"1563208744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBL\" target=\"_blank\">NBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477785-leviathan-natural-gas-platform-on-way-to-israel\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Leviathan natural gas platform on its way to Israel</a></h4><ul><li>Noble Energy (<a href='https://seekingalpha.com/symbol/NBL' title='Noble Energy, Inc.'>NBL</a> <font color='red'>-2.8%</font>) and Delek Drilling (<a href='https://seekingalpha.com/symbol/DKDRF' title='Delek Drilling - Limited Partnership'>OTC:DKDRF</a>) say the first of four giant barges transporting the Leviathan natural gas platform to Israel has <a href=\"https://www.jpost.com/Israel-News/Leviathan-gas-platform-embarks-on-11500-km-journey-to-Israel-595617\" target=\"_blank\">departed the Gulf of Mexico</a> ahead of its planned offshore installation in September.</li><li>Five operational structures - the 38K-ton topsides of the Leviathan  platform \u2013 will make the trans-Atlantic journey, with the remaining barges due to set sail from Texas in the coming weeks.</li><li>After connecting the units to the platform, NBL will start a series of commissioning tests before initiating commercial gas flow to the Israeli market before the end of 2019.</li><li>Leviathan, with 22T cf of reserves, was discovered in 2010 and is one of the world's largest gas discoveries of the past decade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477785\" data-linked=\"Leviathan natural gas platform on its way to Israel\" data-tweet=\"$NBL $DKDRF - Leviathan natural gas platform on its way to Israel https://seekingalpha.com/news/3477785-leviathan-natural-gas-platform-on-way-to-israel?source=tweet\" data-url=\"https://seekingalpha.com/news/3477785-leviathan-natural-gas-platform-on-way-to-israel\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477784\" data-ts=\"1563208724\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477784-cir-cpe-and-glpg-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CIR, CPE and GLPG among midday movers</a></h4><ul><li><strong>Gainers: </strong>Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"green\">+148%</font>. Carolina Trust BancShares (NASDAQ:<a href='https://seekingalpha.com/symbol/CART' title='Carolina Trust BancShares, Inc.'>CART</a>) <font color=\"green\">+30%</font>. SSLJ.com Limited (YGTY) <font color=\"green\">+29%</font>. Chicken Soup for the Soul Entertainment (NASDAQ:<a href='https://seekingalpha.com/symbol/CSSE' title='Chicken Soup for the Soul Entertainment, Inc.'>CSSE</a>) <font color=\"green\">+22%</font>. AVROBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO, Inc.'>AVRO</a>) <font color=\"green\">+22%</font>. Mereo BioPharma Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MREO' title='Mereo BioPharma Group plc'>MREO</a>) <font color=\"green\">+21%</font>. American Electric Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AETI' title='American Electric Technologies, Inc'>AETI</a>) <font color=\"green\">+20%</font>. Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos NV'>GLPG</a>) <font color=\"green\">+18%</font>. CannTrust Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CTST' title='CannTrust Holdings Inc.'>CTST</a>) <font color=\"green\">+15%</font>. Workhorse Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a>) <font color=\"green\">+13%</font>.</li> <li><strong>Losers: </strong>Eton Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ETON' title='Eton Pharmaceuticals, Inc.'>ETON</a>) <font color=\"red\">-15%</font>. Callon Petroleum Company (NYSE:<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Company'>CPE</a>) <font color=\"red\">-15%</font>. Tonix Pharmaceuticals Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-14%</font>. Symantec Corporation (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) <font color=\"red\">-13%</font>. Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"red\">-13%</font>. BIOLASE (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOL' title='BIOLASE, Inc.'>BIOL</a>) <font color=\"red\">-13%</font>. CIRCOR International (NYSE:<a href='https://seekingalpha.com/symbol/CIR' title='CIRCOR International, Inc.'>CIR</a>) <font color=\"red\">-13%</font>. Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) <font color=\"red\">-13%</font>. Medigus (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd.'>MDGS</a>) <font color=\"red\">-12%</font>. SG Blocks (NASDAQ:<a href='https://seekingalpha.com/symbol/SGBX' title='SG Blocks, Inc.'>SGBX</a>) <font color=\"red\">-15%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477784\" data-linked=\"CIR, CPE and GLPG among midday movers\" data-tweet=\"$CAPR $CART $CSSE - CIR, CPE and GLPG among midday movers https://seekingalpha.com/news/3477784-cir-cpe-and-glpg-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477784-cir-cpe-and-glpg-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477783\" data-ts=\"1563208555\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNXP\" target=\"_blank\">TNXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477783-tonix-down-14-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tonix down 14% on equity offering</a></h4><ul><li>Tonix Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a> <font color=\"red\">-14.2%</font>) has filed a <a href=\"https://www.sec.gov/Archives/edgar/data/1430306/000138713119005027/tnxp-s1a_071519.htm\" target=\"_blank\">preliminary prospectus</a> for a public offering of 5.1M common shares at an assumed price of $1.18 per share.</li><li>Friday's close was $1.13.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477783\" data-linked=\"Tonix down 14% on equity offering\" data-tweet=\"$TNXP - Tonix down 14% on equity offering https://seekingalpha.com/news/3477783-tonix-down-14-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3477783-tonix-down-14-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477781\" data-ts=\"1563208004\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYBX\" target=\"_blank\">SYBX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477781-synlogic-up-6-on-positive-synb1618-data-in-pku\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synlogic up 6% on positive SYNB1618 data in PKU</a></h4><ul><li>Thinly traded micro cap Synlogic (<a href='https://seekingalpha.com/symbol/SYBX' title='Synlogic, Inc.'>SYBX</a> <font color=\"green\">+5.9%</font>) is up on modestly higher volume in reaction to <a href=\"https://seekingalpha.com/pr/17570660-synlogic-reports-positive-top-line-data-phase-1-2a-study-synb1618-patients-phenylketonuria\" target=\"_blank\">positive topline data</a> from a Phase 1/2a clinical trial evaluating SYNB1618 in patients with an inborn error of metabolism called <a href=\"https://ghr.nlm.nih.gov/condition/phenylketonuria\" target=\"_blank\">phenylketonuria</a> &#40;PKU&#41; characterized by decreased metabolism of the amino acid phenylalanine.</li><li>A statistically significant increase in biomarkers of SYB1618 activity was observed.</li><li>Complete data will be presented at the Society for the Study of Inborn Errors of Metabolism annual symposium in Rotterdam, September 3-6.</li><li>SYNB1618, what the company calls a Synthetic Biotic medicine, is designed to function in the GI tract where it consumes phenylalanine, metabolizing it into harmless compounds that are eventually excreted in the urine.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477781\" data-linked=\"Synlogic up 6% on positive SYNB1618 data in PKU\" data-tweet=\"$SYBX - Synlogic up 6% on positive SYNB1618 data in PKU https://seekingalpha.com/news/3477781-synlogic-up-6-on-positive-synb1618-data-in-pku?source=tweet\" data-url=\"https://seekingalpha.com/news/3477781-synlogic-up-6-on-positive-synb1618-data-in-pku\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:26 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477773\" data-ts=\"1563207183\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477773-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers:</b> Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"green\">+159%</font>. AVROBIO (NASDAQ:<a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO, Inc.'>AVRO</a>) <font color=\"green\">+22%</font>. Mereo BioPharma Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MREO' title='Mereo BioPharma Group plc'>MREO</a>) <font color=\"green\">+22%</font>. Galapagos (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos NV'>GLPG</a>) <font color=\"green\">+17%</font>. CannTrust Holdings (NYSE:<a href='https://seekingalpha.com/symbol/CTST' title='CannTrust Holdings Inc.'>CTST</a>) <font color=\"green\">+16%</font>.</li><li><b>Losers:</b> Tonix Pharmaceuticals Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-16%</font>. Eton Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ETON' title='Eton Pharmaceuticals, Inc.'>ETON</a>) <font color=\"red\">-15%</font>. Soliton (NASDAQ:<a href='https://seekingalpha.com/symbol/SOLY' title='Soliton, Inc.'>SOLY</a>) <font color=\"red\">-13%</font>. Medigus (NASDAQ:<a href='https://seekingalpha.com/symbol/MDGS' title='Medigus Ltd.'>MDGS</a>) <font color=\"red\">-12%</font>. IMV (NASDAQ:<a href='https://seekingalpha.com/symbol/IMV' title='IMV Inc.'>IMV</a>) <font color=\"red\">-11%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477773\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$CAPR $AVRO $MREO - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3477773-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477773-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477770\" data-ts=\"1563206696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477770-village-farms-international-and-workhorse-among-consumer-gainers-vuzix-and-yeti-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Village Farms International and Workhorse among Consumer gainers;  Vuzix and YETI among losers</a></h4><ul><li><b>Gainers: </b>Village Farms International (NASDAQ:<a href='https://seekingalpha.com/symbol/VFF' title='Village Farms International, Inc.'>VFF</a>) <font color=\"green\">+9%</font>. Workhorse Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WKHS' title='Workhorse Group Inc.'>WKHS</a>) <font color=\"green\">+8%</font>. Crocs (NASDAQ:<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Vuzix (NASDAQ:<a href='https://seekingalpha.com/symbol/VUZI' title='Vuzix Corporation'>VUZI</a>) <font color=\"red\">-11%</font>. YETI (NYSE:<a href='https://seekingalpha.com/symbol/YETI' title='YETI Holdings, Inc.'>YETI</a>) <font color=\"red\">-7%</font>. DAVIDsTEA (NASDAQ:<a href='https://seekingalpha.com/symbol/DTEA' title='DAVIDsTEA Inc.'>DTEA</a>) <font color=\"red\">-6%</font>. Johnson Outdoors (NASDAQ:<a href='https://seekingalpha.com/symbol/JOUT' title='Johnson Outdoors Inc.'>JOUT</a>) <font color=\"red\">-5%</font>. P. H. Glatfelter (NYSE:<a href='https://seekingalpha.com/symbol/GLT' title='P. H. Glatfelter Company'>GLT</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477770\" data-linked=\"Village Farms International and Workhorse among Consumer gainers;  Vuzix and YETI among losers\" data-tweet=\"$VFF $WKHS $CROX - Village Farms International and Workhorse among Consumer gainers; Vuzix and YETI among losers https://seekingalpha.com/news/3477770-village-farms-international-and-workhorse-among-consumer-gainers-vuzix-and-yeti-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477770-village-farms-international-and-workhorse-among-consumer-gainers-vuzix-and-yeti-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477762\" data-ts=\"1563205552\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477762-flexion-up-3-on-new-zilretta-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Flexion up 3% on new Zilretta data</a></h4><ul><li>Flexion Therapeutics (<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color=\"green\">+2.6%</font>) perks up on below-average volume in response to <a href=\"https://seekingalpha.com/pr/17570850-flexion-therapeutics-presents-new-data-evaluating-repeat-administration-zilretta\" target=\"_blank\">new data</a> on the repeat administration of Zilretta (triamcinolone acetonide extended-release injectable suspension) in patients with knee osteoarthritis. The results were presented at the American Orthopedic Society Sports Medicine conference in Boston</li><li>An analysis of 179 patients who received two injections of Zilretta showed a (moderate or greater) response rate of more than 80%, including more than 65% considered substantial responders (at least a 50% reduction in pain at week 12 following each injection).</li><li>The FDA approved Zilretta, administered as a single injection only, in October 2017. The company filed a U.S. application in December 2018 for repeat injections. The agency's action date is October 14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477762\" data-linked=\"Flexion up 3% on new Zilretta data\" data-tweet=\"$FLXN - Flexion up 3% on new Zilretta data https://seekingalpha.com/news/3477762-flexion-up-3-on-new-zilretta-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3477762-flexion-up-3-on-new-zilretta-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477760\" data-ts=\"1563205115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477760-earnings-anxiety-hits-pockets-of-retail\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Earnings anxiety hits pockets of retail</a></h4><ul> <li>Party City (NYSE:<a href='https://seekingalpha.com/symbol/PRTY' title='Party City Holdco Inc.'>PRTY</a>) is <font color=\"red\">down 8.16%</font> as shares threaten to slip below the 52-week low of $6.28</li> <li>The specialty retail sector as a whole is underperforming on the day as Q2 earnings releases near, with Five Below (<a href='https://seekingalpha.com/symbol/FIVE' title='Five Below, Inc.'>FIVE</a> <font color='red'>-2.7%</font>), Zumiez (<a href='https://seekingalpha.com/symbol/ZUMZ' title='Zumiez Inc.'>ZUMZ</a> <font color='red'>-2%</font>), The Container Store (<a href='https://seekingalpha.com/symbol/TCS' title='The Container Store Group, Inc.'>TCS</a> <font color='red'>-2.2%</font>), Urban Outfitters (<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a> <font color='red'>-2.3%</font>), Bed Bath &amp; Beyond (<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a> <font color='red'>-3.2%</font>), Buckle (<a href='https://seekingalpha.com/symbol/BKE' title='The Buckle, Inc.'>BKE</a> <font color='red'>-3%</font>), Hibbett Sports (<a href='https://seekingalpha.com/symbol/HIBB' title='Hibbett Sports, Inc.'>HIBB</a> <font color='red'>-2.9%</font>), Sportsman's Warehouse (<a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-3.7%</font>) and Big Lots (<a href='https://seekingalpha.com/symbol/BIG' title='Big Lots, Inc.'>BIG</a> <font color='red'>-5.8%</font>) all being bid down to start the week.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3477760\" data-linked=\"Earnings anxiety hits pockets of retail\" data-tweet=\"$PRTY $FIVE $ZUMZ - Earnings anxiety hits pockets of retail https://seekingalpha.com/news/3477760-earnings-anxiety-hits-pockets-of-retail?source=tweet\" data-url=\"https://seekingalpha.com/news/3477760-earnings-anxiety-hits-pockets-of-retail\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477755\" data-ts=\"1563204608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYMC\" target=\"_blank\">SYMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477755-ceased-broadcom-symantec-talks-head-scratcher-wedbush\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ceased Broadcom-Symantec talks a &#39;head scratcher&#39; - Wedbush</a></h4><ul><li>Wedbush analyst Daniel Ives questions the <a href=\"https://seekingalpha.com/news/3477679-symantec-minus-17-percent-broadcom-talks-cease-cnbc\" target=\"_blank\">ceased</a> acquisition talks between Broadcom (<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a> <font color='green'>+1.6%</font>) and Symantec (<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a> <font color='red'>-13.3%</font>) due to the \"myriad of challenges the company has on the horizon.\"</li><li>Ives: \"This is a game of high stakes poker and ultimately Symantec\u2019s Board wanted a minimum of $28 per share in a bid which was at the high end of the range ($26-$28) that we believe would have been fair value in a transaction with Broadcom. \"</li><li>Wedbush maintains a Neutral rating on SYMC and a $19 price target. Symantec has a Neutral <a href=\"https://seekingalpha.com/symbol/SYMC/ratings/quant-ratings\" target=\"_blank\">Quant rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477755\" data-linked=\"Ceased Broadcom-Symantec talks a &#39;head scratcher&#39; - Wedbush\" data-tweet=\"$SYMC $AVGO $NLOK - Ceased Broadcom-Symantec talks a &#39;head scratcher&#39; - Wedbush https://seekingalpha.com/news/3477755-ceased-broadcom-symantec-talks-head-scratcher-wedbush?source=tweet\" data-url=\"https://seekingalpha.com/news/3477755-ceased-broadcom-symantec-talks-head-scratcher-wedbush\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477754\" data-ts=\"1563204596\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477754-nielsenplus-4_3-amid-report-kkr-is-nearing-deal-for-company-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nielsen +4.3% amid report KKR is nearing deal for company (updated)</a></h4><ul>   <li>Nielsen Group (<a href=\"http://seekingalpha.com/symbol/NLSN\" target=\"_blank\">NLSN</a> <font color=\"green\">+4.3%</font>) is higher today alongside a report in Intereconomia that <a href='https://seekingalpha.com/symbol/KKR' title='KKR & Co. Inc.'>KKR</a> is close to a deal for the company at $30/share.</li>    <li>That would mark a 26% premium to today's already-higher price.</li>    <li>Nielsen has considered a sale of one of its segments or the company as a whole for some time, though a deal seems to have stalled in April and Nielsen looked to <a href=\"https://seekingalpha.com/news/3462710-nielsen-cuts-sale-price-keep-advent-table-report\" target=\"_blank\">cut its sales price</a> to keep Advent and Goldman Sachs interested in a deal. That was just before Advent was reported to have <a href=\"https://seekingalpha.com/news/3468012-advent-backs-nielsen-bid-dealreporter\" target=\"_blank\">backed out</a>.</li><li><strong>Updated:</strong> Sources are throwing water on the report, with one close to the matter calling it a \"false rumor.\" <a href='https://seekingalpha.com/symbol/NLSN' title='Nielsen Holdings plc'>NLSN</a> has pared gains to <font color=\"green\">+2.3%</font> as of 12:12 p.m.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477754\" data-linked=\"Nielsen +4.3% amid report KKR is nearing deal for company (updated)\" data-tweet=\"$KKR $NLSN - Nielsen +4.3% amid report KKR is nearing deal for company (updated) https://seekingalpha.com/news/3477754-nielsenplus-4_3-amid-report-kkr-is-nearing-deal-for-company-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3477754-nielsenplus-4_3-amid-report-kkr-is-nearing-deal-for-company-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477748\" data-ts=\"1563203647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CROX\" target=\"_blank\">CROX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477748-crocs-rides-piper-jaffray-upgrade-higher\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crocs rides Piper Jaffray upgrade higher</a></h4><ul> <li>Crocs (<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a> <font color='green'>+6.4%</font>) trades higher after landing an upgrade from Piper Jaffray to an Overweight rating.</li> <li>\"Crocs\u2019 outlets have been seeing solid traffic during the summer season &amp; pricing appears to be better vs the April/May season,\" observes analyst Erinn Murphy.</li> <li>Murphy also notes that the Vera Bradley collection at Crocs stores is selling very well.</li> <li>Piper assigns a price target of $27 to Crocs. The <a href=\"https://seekingalpha.com/symbol/CROX/ratings/quant-ratings\" target=\"_blank\">Seeking Alpha Quant Rating</a> on Crox also bullish.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477748\" data-linked=\"Crocs rides Piper Jaffray upgrade higher\" data-tweet=\"$CROX - Crocs rides Piper Jaffray upgrade higher https://seekingalpha.com/news/3477748-crocs-rides-piper-jaffray-upgrade-higher?source=tweet\" data-url=\"https://seekingalpha.com/news/3477748-crocs-rides-piper-jaffray-upgrade-higher\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477740\" data-ts=\"1563203100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALKS\" target=\"_blank\">ALKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477740-alkermes-to-expand-alks-3831-nda-to-include-manic-depression-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alkermes to expand ALKS 3831 NDA to include manic depression; shares up 3%</a></h4><ul><li>Alkermes plc (<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a> <font color=\"green\">+3.3%</font>) is up on below-average volume in response to its its <a href=\"https://seekingalpha.com/pr/17570760-alkermes-expands-planned-new-drug-application-alks-3831-include-treatment-bipolar-disorder\" target=\"_blank\">announcement </a>that it intends to expand its planned U.S. marketing application for ALKS 3831 (olanzapine/samidorphan), originally for schizophrenia, to include bipolar I disorder (manic depression). It expects to file the NDA in Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477740\" data-linked=\"Alkermes to expand ALKS 3831 NDA to include manic depression; shares up 3%\" data-tweet=\"$ALKS - Alkermes to expand ALKS 3831 NDA to include manic depression; shares up 3% https://seekingalpha.com/news/3477740-alkermes-to-expand-alks-3831-nda-to-include-manic-depression-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3477740-alkermes-to-expand-alks-3831-nda-to-include-manic-depression-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477738\" data-ts=\"1563203008\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477738-uniti-slides-on-report-of-master-lease-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uniti slides on report of master lease dispute</a></h4><ul>   <li>Uniti Group (<a href=\"http://seekingalpha.com/symbol/UNIT\" target=\"_blank\">UNIT</a> <font color=\"red\">-9.8%</font>) took a dive on heavy volume in the past 15 minutes, then quickly recouped much of that decline, amid Bloomberg headlines saying Windstream (<a href='https://seekingalpha.com/symbol/WINMQ' title='Windstream Holdings, Inc.'>OTCPK:WINMQ</a>) is looking to reclassify the two's master lease as financing.</li>    <li>The two companies are seeking a mediator on the lease, according to the headlines, because they're \"far apart\" on the status of the lease.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477738\" data-linked=\"Uniti slides on report of master lease dispute\" data-tweet=\"$WINMQ $UNIT - Uniti slides on report of master lease dispute https://seekingalpha.com/news/3477738-uniti-slides-on-report-of-master-lease-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3477738-uniti-slides-on-report-of-master-lease-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>295&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477731\" data-ts=\"1563202457\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHVN\" target=\"_blank\">BHVN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477731-biohaven-up-5-on-publication-of-late-stage-data-on-migraine-med-zydis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biohaven up 5% on publication of late-stage data on migraine med Zydis</a></h4><ul><li>Biohaven Pharmaceutical Holding Company Ltd. (<a href='https://seekingalpha.com/symbol/BHVN' title='Biohaven Pharmaceutical Holding Company Ltd.'>BHVN</a> <font color=\"green\">+4.8%</font>) is up on below-average volume in response the <a href=\"https://seekingalpha.com/pr/17570824-biohavens-positive-phase-3-trial-rimegepant-zydis-orally-dissolving-tablet-acute-treatment\" target=\"_blank\">publication </a>of Phase 3 results on migraine med Zydis (rimegepant) orally dissolving tablet in <em>The Lancet</em>.</li><li>The data showed that treatment with Zydis statistically significantly increased freedom from pain and freedom from the most-bothersome symptom within two hours of a single dose compared to placebo. It demonstrated superiority to placebo on 21 prespecified endpoints.</li><li>All three Phase 3 studies were successful.</li><li>The company filed a U.S. marketing application last quarter with a priority review voucher that permits a six-month review clock.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477731\" data-linked=\"Biohaven up 5% on publication of late-stage data on migraine med Zydis\" data-tweet=\"$BHVN - Biohaven up 5% on publication of late-stage data on migraine med Zydis https://seekingalpha.com/news/3477731-biohaven-up-5-on-publication-of-late-stage-data-on-migraine-med-zydis?source=tweet\" data-url=\"https://seekingalpha.com/news/3477731-biohaven-up-5-on-publication-of-late-stage-data-on-migraine-med-zydis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477725\" data-ts=\"1563201765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNED\" target=\"_blank\">BNED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477725-barnes-noble-educationplus-12-amid-bay-capital-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barnes &amp; Noble Education +12% amid Bay Capital interest</a></h4><ul> <li>Barnes &amp; Noble Education (<a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc.'>BNED</a> <font color='green'>+11.7%</font>) rallies after Bay Capital discloses a series of failed attempts to talks to management about an offer.</li> <li>\"We are perplexed by the Company's refusal to privately engage in good faith negotiations with us regarding several proposals we have made over the past six months to acquire all of the company's outstanding equity at a significant premium\u2014a highly compelling value proposition for stockholders,\" says Bay Capital Managing Partner Sunil Suri,</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3477725\" data-linked=\"Barnes &amp; Noble Education +12% amid Bay Capital interest\" data-tweet=\"$BNED - Barnes &amp; Noble Education +12% amid Bay Capital interest https://seekingalpha.com/news/3477725-barnes-noble-educationplus-12-amid-bay-capital-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3477725-barnes-noble-educationplus-12-amid-bay-capital-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477723\" data-ts=\"1563201494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/C\" target=\"_blank\">C</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477723-analysts-unimpressed-citis-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts unimpressed with Citi&#39;s Q2</a></h4><ul><li>After an initial pre-market advance, Citigroup (<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a> <font color='green'>+0.1%</font>) fell after the market open as analysts weighed in on<a href=\"https://seekingalpha.com/news/3477631-citigroup-eps-beats-0_03-beats-revenue\" target=\"_blank\"> Q2 results</a>; shares have since recovered some during the conference call.</li><li>KBW analyst Brian Kleinhanzl notes net interest margin of 2.66% fell short of KBW's 2.70% estimate and Q1's 2.70%; loan yields and securities yields also missed.</li><li>Q2 results were \"essentially in line,\" writes Credit Suisse's Susan Roth Katzke.</li><li>Jefferies analyst Ken Usdin said that when excluding the Tradeweb gain, \"most items were a little lower\" than consensus estimates.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3477647-citigroups-consumer-unit-bolsters-q2-results\" target=\"_blank\">Citigroup's consumer unit bolsters Q2 results</a> (July 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3477723\" data-linked=\"Analysts unimpressed with Citi&#39;s Q2\" data-tweet=\"$C - Analysts unimpressed with Citi&#39;s Q2 https://seekingalpha.com/news/3477723-analysts-unimpressed-citis-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3477723-analysts-unimpressed-citis-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477713\" data-ts=\"1563200144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UUUU\" target=\"_blank\">UUUU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477713-uranium-names-gain-trump-nixes-import-limits-begins-nuclear-fuel-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uranium names gain as Trump nixes import limits, begins nuclear fuel review</a></h4><ul><li>U.S. uranium producers recoup a little of <a href=\"https://seekingalpha.com/news/3477490-trump-reportedly-will-support-uranium-export-quotas\" target=\"_blank\">last Friday's losses</a> that followed reports Pres. Trump would decline to issue quotas for domestic uranium production, which the White House later <a href=\"https://www.whitehouse.gov/presidential-actions/memorandum-effect-uranium-imports-national-security-establishment-united-states-nuclear-fuel-working-group/\" target=\"_blank\">confirmed</a>; <a href='https://seekingalpha.com/symbol/UUUU' title='Energy Fuels Inc.'>UUUU</a> <font color=\"green\">+2.3%</font>, <a href='https://seekingalpha.com/symbol/URG' title='Ur-Energy Inc.'>URG</a> <font color=\"green\">+4.9%</font> and <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp.'>UEC</a> <font color=\"green\">+6.1%</font> after all lost more than a third of their value on Friday.</li><li>Trump created a working group to review the U.S. nuclear fuel supply chain over the next 90 days, asking to find other ways to boost the domestic uranium industry.</li><li>Petitions from UUUU and URG had sought quotas requiring 25% of the U.S. uranium market be sourced domestically.</li><li>The action could mean uranium production in the U.S. will \"<a href=\"https://www.spglobal.com/platts/en/market-insights/latest-news/electric-power/071319-trump-rejects-uranium-import-limits-but-begins-nuclear-fuel-review\" target=\"_blank\">effectively disappear,</a>\" but it also could bring utilities, which had largely stopped buying uranium because of the uncertainty about whether use of non-U.S. uranium might be curbed, back to the spot market, says Dustin Garrow, managing principal at Nuclear Fuel Associates.</li><li>Electric utility companies with nuclear power plants including Duke Energy (<a href='https://seekingalpha.com/symbol/DUK' title='Duke Energy Corporation'>DUK</a> <font color=\"green\">+0.7%</font>), Entergy (<a href='https://seekingalpha.com/symbol/ETR' title='Entergy Corporation'>ETR</a> <font color=\"green\">+0.4%</font>) and First Energy (<a href='https://seekingalpha.com/symbol/FE' title='FirstEnergy Corp.'>FE</a> <font color='green'>+0.3%</font>) had <a href=\"https://www.reuters.com/article/us-usa-trade-uranium/trump-declines-to-set-u-s-uranium-production-quotas-idUSKCN1U8032\" target=\"_blank\">fought against</a> the miners' petitions, arguing their costs would rise if they were forced to source U.S. uranium.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLU' title='Utilities Select Sector SPDR ETF'>XLU</a>, <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a>, <a href='https://seekingalpha.com/symbol/UTG' title='Reaves Utility Income Fund'>UTG</a>, <a href='https://seekingalpha.com/symbol/VPU' title='Vanguard Utilities ETF'>VPU</a>, <a href='https://seekingalpha.com/symbol/GUT' title='Gabelli Utility Trust'>GUT</a>, <a href='https://seekingalpha.com/symbol/IDU' title='iShares U.S. Utilities ETF'>IDU</a>, <a href='https://seekingalpha.com/symbol/BUI' title='BlackRock Utility&Infrastructure Trust'>BUI</a>, <a href='https://seekingalpha.com/symbol/NLR' title='VanEck Vectors Uranium+Nuclear Energy ETF'>NLR</a>, <a href='https://seekingalpha.com/symbol/FUTY' title='Fidelity MSCI Utilities Index ETF'>FUTY</a>, <a href='https://seekingalpha.com/symbol/RYU' title='Invesco S&P Equal Weight Utilities ETF'>RYU</a>, <a href='https://seekingalpha.com/symbol/UPW' title='ProShares Ultra Utilities ETF'>UPW</a>, <a href='https://seekingalpha.com/symbol/FXU' title='First Trust Utilities AlphaDEX ETF'>FXU</a>, <a href='https://seekingalpha.com/symbol/SDP' title='ProShares UltraShort Utilities ETF'>SDP</a>, <a href='https://seekingalpha.com/symbol/FUGAX' title='Fidelity Advisor® Utilities Fund A'>FUGAX</a>, <a href='https://seekingalpha.com/symbol/JHMU' title='John Hancock Multifactor Utilities ETF'>JHMU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3477713\" data-linked=\"Uranium names gain as Trump nixes import limits, begins nuclear fuel review\" data-tweet=\"$UUUU $URG $UEC - Uranium names gain as Trump nixes import limits, begins nuclear fuel review https://seekingalpha.com/news/3477713-uranium-names-gain-trump-nixes-import-limits-begins-nuclear-fuel-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3477713-uranium-names-gain-trump-nixes-import-limits-begins-nuclear-fuel-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>81&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477703\" data-ts=\"1563199146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVRO\" target=\"_blank\">AVRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477703-avrobio-up-8-on-positive-gene-therapy-data-in-fabry\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avrobio up 8% on positive gene therapy data in Fabry</a></h4><ul><li>Thinly traded AVROBIO (<a href='https://seekingalpha.com/symbol/AVRO' title='AVROBIO, Inc.'>AVRO</a> <font color=\"green\">+7.9%</font>) is up on increased volume in early trade following its <a href=\"https://seekingalpha.com/pr/17570727-avrobio-announces-87-percent-substrate-reduction-first-kidney-biopsy-additional-positive-data\" target=\"_blank\">announcement </a>of additional positive data and the first kidney biopsy results from its two ongoing clinical trials evaluating gene therapy candidate AVR-RD-01 in patients with an inherited disorder called <a href=\"https://ghr.nlm.nih.gov/condition/fabry-disease\" target=\"_blank\">Fabry disease</a>, characterized by the buildup of a type of fat (globotriaosylceramide or Gb3) in the body's cells.</li><li>Eight patients have been dosed to date, five in the Phase 1 FACTs study and three in Phase 2 <a href=\"https://clinicaltrials.gov/ct2/show/NCT03454893?lead=avrobio&amp;rank=1\" target=\"_blank\">FAB-201</a>.</li><li>The primary endpoint in FAB-201 is the change from baseline in the average number of Gb3 inclusions per peritubular capillary as measured in a kidney biopsy one year post-treatment.</li><li>The first treated patient in FAB-201 showed an 87% reduction in Gb3 substrate in the kidney and an 87% reduction in plasma lyso-Gb3 at year one (data on the other two not provided). The first four in the Phase 1 study experienced plasma lyso-Gb3 reductions of 33 - 41% from baseline (data on the fifth not provided).</li><li>The treatment effect was sustained across multiple parameters. Kidney and cardiac functions were stable and in the normal range in the first Phase 2 patient at one year.</li><li>No new safety signals were observed.</li><li>Development is ongoing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477703\" data-linked=\"Avrobio up 8% on positive gene therapy data in Fabry\" data-tweet=\"$AVRO - Avrobio up 8% on positive gene therapy data in Fabry https://seekingalpha.com/news/3477703-avrobio-up-8-on-positive-gene-therapy-data-in-fabry?source=tweet\" data-url=\"https://seekingalpha.com/news/3477703-avrobio-up-8-on-positive-gene-therapy-data-in-fabry\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477704\" data-ts=\"1563199102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TKR\" target=\"_blank\">TKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477704-timkenminus-2-after-bofa-downgrades-timken\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Timken -2% after BofA downgrades Timken</a></h4><ul><li>With shares of Timken (NYSE:<a href='https://seekingalpha.com/symbol/TKR' title='The Timken Company'>TKR</a>) up 30% YTD, BofA analyst Ross Gilardi downgraded the stock to Buy from Neutral, leading shares to <font color=\"red\">fall 2%</font> in early trade.</li><li>The rating is based on the expectation that the company will trim its outlook for 2019 due to softer auto and short cycle data.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477704\" data-linked=\"Timken -2% after BofA downgrades Timken\" data-tweet=\"$TKR - Timken -2% after BofA downgrades Timken https://seekingalpha.com/news/3477704-timkenminus-2-after-bofa-downgrades-timken?source=tweet\" data-url=\"https://seekingalpha.com/news/3477704-timkenminus-2-after-bofa-downgrades-timken\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477698\" data-ts=\"1563198542\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIXY\" target=\"_blank\">PIXY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477698-shiftpixy-slides-after-delaying-earnings-release\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ShiftPixy slides after delaying earnings release</a></h4><ul><li>Shares of ShiftPixy (NASDAQ:<a href='https://seekingalpha.com/symbol/PIXY' title='ShiftPixy, Inc.'>PIXY</a>) are down <font color=\"red\">16.83%</font> after the company postpones the release date for FQ3 earnings.</li><li>ShiftPixy says it will provide a new date for the release as soon as possible.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3477698\" data-linked=\"ShiftPixy slides after delaying earnings release\" data-tweet=\"$PIXY - ShiftPixy slides after delaying earnings release https://seekingalpha.com/news/3477698-shiftpixy-slides-after-delaying-earnings-release?source=tweet\" data-url=\"https://seekingalpha.com/news/3477698-shiftpixy-slides-after-delaying-earnings-release\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477695\" data-ts=\"1563197955\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477695-l-brands-dips-after-citi-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L Brands dips after Citi cut</a></h4><ul> <li>L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='red'>-0.9%</font>) trades lower after Citi downgrades the retailer to a Neutral rating from Buy and drops its price target to $27.</li> <li>Citi warns cultural norms are shifting away from the Victoria's Secret brand and sees toughs comparisons ahead.</li> <li>Separately on the public relations front, Victoria's Secret has been <a href=\"https://www.businessinsider.sg/model-escaped-epstein-he-was-in-charge-of-victorias-secret-2019-7/\" target=\"_blank\">mentioned</a> in some media reports on the Jeffrey Epstein scandal.</li> <li>Shares of L Brands are down about 5% over the last week.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477695\" data-linked=\"L Brands dips after Citi cut\" data-tweet=\"$LB - L Brands dips after Citi cut https://seekingalpha.com/news/3477695-l-brands-dips-after-citi-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3477695-l-brands-dips-after-citi-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477687\" data-ts=\"1563197331\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477687-strong-ag-outlook-bofa-upgrade-deere\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strong ag outlook has BofA upgrade Deere</a></h4><ul><li>\"Ultimately, Deere is an ag story but construction still accounts for over 30% of revenue. Deere dealer retail sales for NA construction equipment were up double-digit in June on a trailing three month basis, and our survey work suggests that dealer inventories are still balanced,\" according to Bank of America, which upgraded the stock to Buy from Neutral.</li><li>\"Meanwhile, the ag outlook into FY20 looks increasingly strong on surging grain prices, at a time when industrial earnings growth could be a scarce commodity in 2020.\"</li><li>DE <font color=\"green\">+1.1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3477687\" data-linked=\"Strong ag outlook has BofA upgrade Deere\" data-tweet=\"Strong ag outlook has BofA upgrade Deere https://seekingalpha.com/news/3477687-strong-ag-outlook-bofa-upgrade-deere?source=tweet\" data-url=\"https://seekingalpha.com/news/3477687-strong-ag-outlook-bofa-upgrade-deere\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477682\" data-ts=\"1563197083\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKS\" target=\"_blank\">AKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477682-trump-to-increase-use-of-american-steel-in-infrastructure-projects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump to increase use of American steel in infrastructure projects</a></h4><ul><li>Steel producers are higher after the White House says Pres. Trump will <a href=\"https://thehill.com/homenews/administration/427817-trump-signs-order-to-boost-federal-purchases-of-iron-steel\" target=\"_blank\">sign an executive order</a> this week designed to increase the amount of  American steel and iron used in infrastructure projects; <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corporation'>AKS</a> <font color=\"green\">+2.3%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color=\"green\">+1.9%</font>, <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color=\"green\">+1.7%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color=\"green\">+1%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs Inc.'>CLF</a> <font color=\"green\">+0.8%</font>, <a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color=\"green\">+0.7%</font>.</li><li>The order will direct agency heads to \"encourage recipients of new federal  financial assistance awards to use, to the greatest extent practical,  iron, steel, aluminum, cement and other manufacturing products\" produced  in the U.S., according to trade advisor Peter Navarro.</li><li>ETF: <a href='https://seekingalpha.com/symbol/SLX' title='VanEck Vectors Steel ETF'>SLX</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3477682\" data-linked=\"Trump to increase use of American steel in infrastructure projects\" data-tweet=\"$AKS $STLD $MT - Trump to increase use of American steel in infrastructure projects https://seekingalpha.com/news/3477682-trump-to-increase-use-of-american-steel-in-infrastructure-projects?source=tweet\" data-url=\"https://seekingalpha.com/news/3477682-trump-to-increase-use-of-american-steel-in-infrastructure-projects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477672\" data-ts=\"1563196969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZSAN\" target=\"_blank\">ZSAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477672-zosano-up-6-premarket-on-positive-qtrytpa-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zosano up 6% premarket on positive Qtrytpa data</a></h4><ul><li>Nano cap Zosano Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/ZSAN' title='Zosano Pharma Corporation'>ZSAN</a>) is up <font color=\"green\">6%</font> premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17570676-zosano-pharma-presents-migraine-act-scores-qtrypta-american-headache-society-ahs-annual\" target=\"_blank\">announcement </a>of positive data on migraine candidate Qtrypta (zolmitriptan). The results were presented at the American Headache Society Annual Scientific Meeting in Philadelphia.</li><li>Data from a questionnaire called Migraine-ACT from 294 patients were presented. 96% reported that Qtrypta worked consistently the majority of the time, 85% reported that their headache pain disappeared within two hours, 84% reported that they were able to function normally within two hours and 94% were comfortable enough with the medication to plan their daily activities.</li><li><a href=\"https://www.zosanopharma.com/technology/\" target=\"_blank\">Qtrypta</a> is a patch worn on the skin that delivers zolmitriptan subcutaneously via drug-coated microprojections mounted on the facing of the patch.</li><li>The company plans to file a U.S. marketing application in Q4.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477672\" data-linked=\"Zosano up 6% premarket on positive Qtrytpa data\" data-tweet=\"$ZSAN - Zosano up 6% premarket on positive Qtrytpa data https://seekingalpha.com/news/3477672-zosano-up-6-premarket-on-positive-qtrytpa-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3477672-zosano-up-6-premarket-on-positive-qtrytpa-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477680\" data-ts=\"1563196715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477680-symc-cpe-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SYMC, CPE among premarket losers</a></h4><ul><li>Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) <font color=\"red\">-17%</font> as <a href=\"https://seekingalpha.com/news/3477679-symantec-minus-17-percent-broadcom-talks-cease-cnbc\" target=\"_blank\">Broadcom</a> talks cease.</li><li>CIRCOR International (NYSE:<a href='https://seekingalpha.com/symbol/CIR' title='CIRCOR International, Inc.'>CIR</a>) <font color=\"red\">-14%</font> after Crane <a href=\"https://seekingalpha.com/news/3477617-crane-ends-pursuit-circor-cir-minus-14-percent\" target=\"_blank\">ceasing efforts</a> to acquire CIRCOR.</li><li>Callon Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Company'>CPE</a>) <font color=\"red\">-12%</font> on announcing <a href=\"https://seekingalpha.com/news/3477615-callon-petroleum-buy-carrizo-oil-and-gas-3_2b-deal\" target=\"_blank\">acquisition</a> of Carrizo Oil &amp; Gas for $3.2B.</li><li>SG Blocks (NASDAQ:<a href='https://seekingalpha.com/symbol/SGBX' title='SG Blocks, Inc.'>SGBX</a>) <font color=\"red\">-12%</font> after forming a <a href=\"https://seekingalpha.com/pr/17570983-sg-blocks-geis-companies-form-teaming-agreement\" target=\"_blank\">strategic alliance</a> with Geis Companies.</li><li>So-Young International (NASDAQ:<a href='https://seekingalpha.com/symbol/SY' title='So-Young International Inc.'>SY</a>) <font color=\"red\">-8%</font>.</li><li>Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3477671-jaguar-health-files-equity-offering-shares-8-percent-premarket\" target=\"_blank\">filing</a> equity offering.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"red\">-7%</font>.</li><li>Eros International (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) <font color=\"red\">-5%</font> on <a href=\"https://seekingalpha.com/news/3477637-eros-international-reports-q4-results\" target=\"_blank\">Q4 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477680\" data-linked=\"SYMC, CPE among premarket losers\" data-tweet=\"$NLOK $CIR $CPE - SYMC, CPE among premarket losers https://seekingalpha.com/news/3477680-symc-cpe-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477680-symc-cpe-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477679\" data-ts=\"1563196652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYMC\" target=\"_blank\">SYMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477679-symantecminus-17-broadcom-talks-cease-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Symantec -17% as Broadcom talks cease (update)</a></h4><ul><li>Update: Bloomberg's Ed Hammond <a href=\"https://twitter.com/EdHammondNY/status/1150778461671362560\" target=\"_blank\">was told</a> the deal was good for $28.25/share as recently as this weekend, but Broadcomm found something in due diligence that cut the offer by $1.50 to $2 per share.</li><li>CNBC <a href=\"https://www.cnbc.com/2019/07/15/symantec-and-broadcom-cease-deal-negotiations-sources.html\" target=\"_blank\">sources</a> say Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) and Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) have ended deal talks because SYMC wouldn't accept less than $28/share.</li><li>Symantec shares plunge <font color=\"red\">17.1%</font> pre-market to $21.20. AVGO <font color=\"green\">gains 2.7%</font> to $293.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477679\" data-linked=\"Symantec -17% as Broadcom talks cease (update)\" data-tweet=\"$SYMC $AVGO $NLOK - Symantec -17% as Broadcom talks cease (update) https://seekingalpha.com/news/3477679-symantecminus-17-broadcom-talks-cease-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3477679-symantecminus-17-broadcom-talks-cease-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477678\" data-ts=\"1563196568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCEL\" target=\"_blank\">FCEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477678-fuelcell-warns-of-potential-bankruptcy-amid-financing-squeeze\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FuelCell warns of potential bankruptcy amid financing squeeze</a></h4><ul><li>FuelCell Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/FCEL' title='FuelCell Energy, Inc.'>FCEL</a>) <font color=\"red\">-19.2%</font> pre-market after <a href=\"https://www.sec.gov/Archives/edgar/data/886128/000156459019024900/fcel-8k_20190711.htm\" target=\"_blank\">warning about its liquidity position</a>, saying it has \"significant short-term debt and other obligations currently due or maturing in less than one year which are in excess of the company's cash and current asset balance.\"</li><li>FCEL says it may be unable to refinance the Hercules credit facility; although the maturity date of the facility is April 1, 2020, FCEL says it may not meet certain covenant requirements if it is unable to refinance the Hercules credit facility by Aug. 9, 2019, which could result in a default.</li><li>FCEL says it may sell as much as $42M of common stock in an at-the-market sales plan, and plans to use any proceeds to pay down debt, including the Hercules facility and its loan from NRG Energy.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477678\" data-linked=\"FuelCell warns of potential bankruptcy amid financing squeeze\" data-tweet=\"$FCEL - FuelCell warns of potential bankruptcy amid financing squeeze https://seekingalpha.com/news/3477678-fuelcell-warns-of-potential-bankruptcy-amid-financing-squeeze?source=tweet\" data-url=\"https://seekingalpha.com/news/3477678-fuelcell-warns-of-potential-bankruptcy-amid-financing-squeeze\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477676\" data-ts=\"1563196367\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477676-uec-adxs-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UEC, ADXS among premarket gainers</a></h4><ul><li>Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) <font color=\"green\">+95% </font>on positive <a href=\"https://seekingalpha.com/news/3477600-capricor-45-percent-premarket-positive-capminus-1002-data\" target=\"_blank\">CAP-1002 data</a>.</li><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos NV'>GLPG</a>) <font color=\"green\">+19%</font> on Gilead <a href=\"https://seekingalpha.com/news/3477596-galapagos-16-percent-premarket-gilead-deal\" target=\"_blank\">deal</a>.</li><li>Neon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics, Inc.'>NTGN</a>) <font color=\"green\">+15%</font> on neoantigen cancer vaccine <a href=\"https://seekingalpha.com/news/3477664-neon-13-percent-premarket-neoantigen-cancer-vaccine-data\" target=\"_blank\">data</a>.</li><li>Advaxis (NASDAQ:<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis, Inc.'>ADXS</a>) <font color=\"green\">+11%</font> as <a href=\"https://seekingalpha.com/pr/17570878-new-immune-data-ongoing-adxs-neo-phase-1-study-support-clinical-potential-neoantigen-directed\" target=\"_blank\">new immune data</a> from its ongoing ADXS-NEO Phase 1 clinical trial that further support the clinical potential for the neoantigen-directed immunotherapies.</li><li>Carrizo Oil &amp; Gas (NASDAQ:<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a>) <font color=\"green\">+11%</font> on being <a href=\"https://seekingalpha.com/news/3477615-callon-petroleum-buy-carrizo-oil-and-gas-3_2b-deal\" target=\"_blank\">acquired</a> by Callon Petroleum.</li><li>American Electric Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AETI' title='American Electric Technologies, Inc'>AETI</a>) <font color=\"green\">+13%</font>.</li><li>Energy Fuels (NYSEMKT:<a href='https://seekingalpha.com/symbol/UUUU' title='Energy Fuels Inc.'>UUUU</a>) <font color=\"green\">+10%</font> as <a href=\"https://seekingalpha.com/pr/17570699-energy-fuels-commends-president-trump-decision-reinvigorate-nuclear-fuel-supply-chain-looks\" target=\"_blank\">petition filed</a> jointly with Ur-Energy under Section 232 of the Trade Expansion Act of 1962, has been very successful.</li><li>Uranium Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp.'>UEC</a>) <font color=\"green\">+8%</font>.</li><li>Remark Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MARK' title='Remark Holdings, Inc.'>MARK</a>) <font color=\"green\">+6%</font>.</li><li>Crocs (NASDAQ:<a href='https://seekingalpha.com/symbol/CROX' title='Crocs, Inc.'>CROX</a>) <font color=\"green\">+5%</font> on a <a href=\"https://seekingalpha.com/pr/17571145-crocs-chinatown-market-release-limited-edition-clog-urban-outfitters\" target=\"_blank\">second product collaboration</a> with Chinatown Market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477676\" data-linked=\"UEC, ADXS among premarket gainers\" data-tweet=\"$CAPR $GLPG $NTGN - UEC, ADXS among premarket gainers https://seekingalpha.com/news/3477676-uec-adxs-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3477676-uec-adxs-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477671\" data-ts=\"1563196194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAGX\" target=\"_blank\">JAGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477671-jaguar-health-files-for-equity-offering-shares-down-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jaguar Health files for equity offering; shares down 8% premarket</a></h4><ul><li>Jaguar Health (NASDAQ:<a href='https://seekingalpha.com/symbol/JAGX' title='Jaguar Health, Inc.'>JAGX</a>) has filed a preliminary <a href=\"https://www.sec.gov/Archives/edgar/data/1585608/000104746919004164/a2239230zs-1a.htm\" target=\"_blank\">prospectus</a> for public offering of 3,519,061 Class A Units, each consisting of one common share and warrant to purchase one common share, and 12K Class B Units, each consisting of one share of Series B Convertible Preferred Stock (valued at $1,000) and the equivalent number of warrants if the purchaser had bought Class A Units.</li><li>The Offering price per Class A and Class B unit is $3.41 and $1000, respectively.</li><li>Underwriters over-allotment is an additional 527,859 Common and/or Series B Convertible Preferred Stock, and warrants to purchase up to 527,859 common shares.</li><li>Net proceeds of ~$10.2M will be used for debt repayment and for general corporate purposes, including working capital.</li><li>Shares are down <font color=\"red\">8%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477671\" data-linked=\"Jaguar Health files for equity offering; shares down 8% premarket\" data-tweet=\"$JAGX - Jaguar Health files for equity offering; shares down 8% premarket https://seekingalpha.com/news/3477671-jaguar-health-files-for-equity-offering-shares-down-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3477671-jaguar-health-files-for-equity-offering-shares-down-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477670\" data-ts=\"1563196010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477670-m-premium-wears-off-thai-beverage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">M&amp;A premium wears off Thai Beverage</a></h4><ul> <li>Thai Beverage (<a href='https://seekingalpha.com/symbol/TBVPF' title='Thai Beverage Public Company Limited'>OTCPK:TBVPF</a>) <font color=\"red\">fell another 2.31%</font> today in Singapore trading after Anheuser-Busch InBev pulled the IPO for its Asian operations.</li> <li>Thai Beverage was seen as a potential target for Budweiser Brewing Company (<a href='https://seekingalpha.com/symbol/BUDBC' title='Budweiser Brewing Company'>BUDBC</a>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3477670\" data-linked=\"M&amp;A premium wears off Thai Beverage\" data-tweet=\"$TBVPF $BUDBC - M&amp;A premium wears off Thai Beverage https://seekingalpha.com/news/3477670-m-premium-wears-off-thai-beverage?source=tweet\" data-url=\"https://seekingalpha.com/news/3477670-m-premium-wears-off-thai-beverage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477669\" data-ts=\"1563195848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLBS\" target=\"_blank\">CLBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477669-caladrius-bio-up-8-premarket-on-accelerated-review-status-for-clbs12-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caladrius Bio up 8% premarket on accelerated review status for CLBS12 in Europe</a></h4><ul><li>Thinly traded nano cap Caladrius Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CLBS' title='Caladrius Biosciences, Inc.'>CLBS</a>) is up <font color=\"green\">8% </font>premarket on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/17571064-caladrius-biosciences-receives-advanced-therapy-medicinal-product-classification-clbs12-cd34\" target=\"_blank\">announcement </a>that the European Medicines Agency &#40;EMA&#41; has granted Advanced Therapy Medicinal Product &#40;ATMP&#41; status for cell therapy candidate <a href=\"https://www.caladrius.com/product-candidates/clbs12/\" target=\"_blank\">CLBS12 </a>for the potential treatment of <a href=\"https://vascularcures.org/critical-limb-ischemia-cli/\" target=\"_blank\">critical limb ischemia</a> (low blood flow to the lower extremities due to severely blockage of arteries).</li><li>Benefits of ATMP status include more intensive EMA guidance on development and fee reductions for regulatory advice.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477669\" data-linked=\"Caladrius Bio up 8% premarket on accelerated review status for CLBS12 in Europe\" data-tweet=\"$CLBS - Caladrius Bio up 8% premarket on accelerated review status for CLBS12 in Europe https://seekingalpha.com/news/3477669-caladrius-bio-up-8-premarket-on-accelerated-review-status-for-clbs12-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3477669-caladrius-bio-up-8-premarket-on-accelerated-review-status-for-clbs12-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477665\" data-ts=\"1563194956\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BOOT\" target=\"_blank\">BOOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477665-boot-barnminus-2-after-citi-warns-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Boot Barn -2% after Citi warns on valuation</a></h4><ul> <li>Shares of Boot Barn (NYSE:<a href='https://seekingalpha.com/symbol/BOOT' title='Boot Barn Holdings, Inc.'>BOOT</a>) slip after Citi lowers the retailer to a Neutral rating from Buy due to the high valuation at the current share price.</li> <li>The <a href=\"https://seekingalpha.com/symbol/BOOT/ratings/quant-ratings\" target=\"_blank\">Seeking Alpha Quant Rating</a> on BOOT is still Bullish despite the 108% YTD run.</li> <li>BOOT <font color=\"red\">-1.95%</font> premarket to $34.75.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477665\" data-linked=\"Boot Barn -2% after Citi warns on valuation\" data-tweet=\"$BOOT - Boot Barn -2% after Citi warns on valuation https://seekingalpha.com/news/3477665-boot-barnminus-2-after-citi-warns-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3477665-boot-barnminus-2-after-citi-warns-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477664\" data-ts=\"1563194799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTGN\" target=\"_blank\">NTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477664-neon-up-13-premarket-on-neoantigen-cancer-vaccine-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neon up 13% premarket on neoantigen cancer vaccine data</a></h4><ul><li>Thinly traded micro cap Neon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics, Inc.'>NTGN</a>) is up <font color=\"green\">13% </font>premarket on modestly higher volume in reaction to <a href=\"https://seekingalpha.com/pr/17570677-neon-therapeutics-personal-neoantigen-vaccine-study-demonstrates-prolonged-progression-free\" target=\"_blank\">positive topline results</a> from a Phase 1b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02897765?lead=neon+therapeutics&amp;phase=0&amp;rank=3\" target=\"_blank\">NT-001</a>, evaluating NEO-PV-01, its personal neoantigen vaccine candidate, combined with Bristol-Myers Squibb's Opdivo (nivolumab), in patients with advanced/metastatic melanoma, smoking-associated non-small lung cancer &#40;NSCLC&#41; or bladder cancer.</li><li>Median progression-free survival &#40;PFS&#41; had not been readed at a median follow-up of 13.4 months in 34 metastatic melanoma patients. Median PFS was 5.6 months in 27 metastatic NSCLC patients (median follow-up of 12.0 months) and 21 metastatic bladder cancer patients (median follow-up of 14.7 months).</li><li>The response rates were 47%, 22% and 24%, respectively.</li><li>Development is ongoing. More detailed data will be submitted for presentation at a future medical conference.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477664\" data-linked=\"Neon up 13% premarket on neoantigen cancer vaccine data\" data-tweet=\"$NTGN - Neon up 13% premarket on neoantigen cancer vaccine data https://seekingalpha.com/news/3477664-neon-up-13-premarket-on-neoantigen-cancer-vaccine-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3477664-neon-up-13-premarket-on-neoantigen-cancer-vaccine-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:46 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477648\" data-ts=\"1563193424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477648-erosminus-6-on-q4-softness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros -6% on Q4 softness</a></h4><ul><li>Eros (NYSE:<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a>) <font color=\"red\">drops 6%</font> pre-market after the Q4 report featured a 46% Y/Y drop in adjusted EBITDA to $13.1M.</li><li>Net debt totaled $145M (down $14.1M on the quarter) and cash and equivalents were $135.8M at the end of the quarter.</li><li>EROS says its review for strategic alternatives remains ongoing.</li><li>Earnings call starts at 8:30 AM ET with a webcast <a href=\"https://erosplc.gcs-web.com/events-and-presentations/upcoming-events\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17570870-eros-international-plc-reports-fourth-quarter-fiscal-year-end-2019-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477648\" data-linked=\"Eros -6% on Q4 softness\" data-tweet=\"$EROS - Eros -6% on Q4 softness https://seekingalpha.com/news/3477648-erosminus-6-on-q4-softness?source=tweet\" data-url=\"https://seekingalpha.com/news/3477648-erosminus-6-on-q4-softness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477647\" data-ts=\"1563193406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/C\" target=\"_blank\">C</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477647-citigroups-consumer-unit-bolsters-q2-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citigroup&#39;s consumer unit bolsters Q2 results</a></h4><ul><li>Citigroup (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>)<font color=\"green\"> rises 0.8% </font>in premarket trading after <a href=\"https://seekingalpha.com/pr/17570869-citigroup-reports-second-quarter-2019-results\" target=\"_blank\">Q2 adjusted EPS</a> of $1.83, excluding a gain on its investment in Tradeweb, beat the average analyst estimate of $1.80;</li><li>Q2 revenue rose 2% Y/Y to $18.8B, reflecting ~$350 million pretax gain on Citi's investment in Tradeweb within Fixed Income Markets and higher revenues across Global Consumer Banking partially offset by declines in Investment Banking and Fixed Income<i>,</i> and Equity Markets revenues, as well as mark-to-market losses on loan hedges.</li><li>Q2 revenue increased 1% from Q1 2019.</li><li>Operating expenses of $10.5B during the quarter declined by 2% Y/Y.</li><li>Cost of credit of $2.1B increased 16% Y/Y, driven by volume growth and seasoning in Citi-branded Cards and Citi Retail Services in North America Global Consumer Banking as wall as credit normalization in Institutional Clients Group.</li><li>Revenue by segment:</li></ul><ol><li>Global consumer banking $8.61B, up 1% Q/Q and up 3% Y/Y.</li><li>Treasury &amp; trade solutions revenue of $2.44B rose 2% Q/Q and 4% Y/Y.</li><li>Fixed-income markets revenue of $3.32B fell 4% Q/Q and rose 8% Y/Y.</li><li>Equity markets revenue of $790M fell 6% Q/Q and fell 9% Y/Y.</li></ol><ul><li>Q2 return on average common equity of 10.1% compares with 10.2% in Q1 and 9.2% in Q2 2018.</li><li><a href=\"https://edge.media-server.com/mmc/p/9g2hdaxz\" target=\"_blank\">Conference call</a> at 10:00 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3477631-citigroup-eps-beats-0_03-beats-revenue\" target=\"_blank\">Citigroup EPS beats by $0.03, beats on revenue</a> (July 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3477647\" data-linked=\"Citigroup&#39;s consumer unit bolsters Q2 results\" data-tweet=\"$C - Citigroup&#39;s consumer unit bolsters Q2 results https://seekingalpha.com/news/3477647-citigroups-consumer-unit-bolsters-q2-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3477647-citigroups-consumer-unit-bolsters-q2-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477634\" data-ts=\"1563192126\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBAC\" target=\"_blank\">SBAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477634-keybanc-boosts-sba-on-tower-valuations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KeyBanc boosts SBA on tower valuations</a></h4><ul><li>KeyBanc raises its SBA Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/SBAC' title='SBA Communications Corporation'>SBAC</a>) target from $215 to $252 while maintaining an Overweight rating.</li><li>Analyst Brandon Nispel says peak tower valuations haven't been reached. He sees ample growth opportunities and no risks to Q2 and FY19 estimates.</li><li>SBAC shares are <font color=\"red\">down 0.9%</font> pre-market to $231.93.</li><li>SBA has an Outperform average <a href=\"https://seekingalpha.com/symbol/SBAC/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477634\" data-linked=\"KeyBanc boosts SBA on tower valuations\" data-tweet=\"$SBAC - KeyBanc boosts SBA on tower valuations https://seekingalpha.com/news/3477634-keybanc-boosts-sba-on-tower-valuations?source=tweet\" data-url=\"https://seekingalpha.com/news/3477634-keybanc-boosts-sba-on-tower-valuations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477631\" data-ts=\"1563192018\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/C\" target=\"_blank\">C</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477631-citigroup-eps-beats-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citigroup EPS beats by $0.03, beats on revenue</a></h4><ul><li>Citigroup (NYSE:<a href='https://seekingalpha.com/symbol/C' title='Citigroup Inc.'>C</a>): Q2 Non-GAAP EPS of $1.83 <font color=\"green\">beats by $0.03</font>; GAAP EPS of $1.94 <font color=\"green\">beats by $0.13</font>.</li><li>Revenue of $18.76B (+1.6% Y/Y) <font color=\"green\">beats by $270M</font>.</li><li>Shares <font color=\"green\">+1.1%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17570869-citigroup-reports-second-quarter-2019-results\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3477631\" data-linked=\"Citigroup EPS beats by $0.03, beats on revenue\" data-tweet=\"$C - Citigroup EPS beats by $0.03, beats on revenue https://seekingalpha.com/news/3477631-citigroup-eps-beats-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3477631-citigroup-eps-beats-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477626\" data-ts=\"1563191072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477626-ubs-takes-breather-on-ge-sharesminus-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UBS &#39;takes a breather&#39; on GE; shares -1%</a></h4><ul><li>General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric Company'>GE</a>) <font color=\"red\">-1.1%</font> premarket after UBS <a href=\"https://www.thestreet.com/investing/stocks/general-electric-shares-slide-after-ubs-downgrade-industrial-cash-flow-trim-15018798\" target=\"_blank\">advised</a> investors to \"take a breather after recent stock outperformance\" amid the industrial group's ongoing turnaround.</li><li>Analyst Damian Karas cut his rating on the stock to Neutral from Buy, lowered his PT to $11.50 from $13.00 per share and reduced his forecast for 2019 industrial free-cash flow to -$1.5B.</li><li>He also sees a cash burn rate of between $1B-$2B over the second quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477626\" data-linked=\"UBS &#39;takes a breather&#39; on GE; shares -1%\" data-tweet=\"$GE - UBS &#39;takes a breather&#39; on GE; shares -1% https://seekingalpha.com/news/3477626-ubs-takes-breather-on-ge-sharesminus-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3477626-ubs-takes-breather-on-ge-sharesminus-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477623\" data-ts=\"1563190709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKRO\" target=\"_blank\">AKRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477623-wells-sees-33-upside-in-gilead-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells sees 33% upside in Gilead in premarket analyst action</a></h4><ul><li>Akero Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AKRO' title='Akero Therapeutics, Inc.'>AKRO</a>) initiated with Buy rating and $28 (41% upside) price target at Jefferies. Shares down a fraction premarket.</li><li>Atreca (NASDAQ:<a href='https://seekingalpha.com/symbol/BCEL' title='Atreca, Inc.'>BCEL</a>) initiated with Buy rating and $23 (38% upside) price target at Canaccord Genuity. Initiated with Buy rating and $28 price target at Cowen. Initiated with Outperform rating and $35 price target at Evercore ISI.</li><li>Personalis (NASDAQ:<a href='https://seekingalpha.com/symbol/PSNL' title='Personalis, Inc.'>PSNL</a>) initiated with Overweight rating and $28 (10% upside) price target at Morgan Stanley. Initiated with Outperform rating at Cowen. Initiated with Outperform rating and $29 price target at Oppenheimer. Shares down <font color=\"red\">1% </font>premarket.</li><li>Prevail Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PRVL' title='Prevail Therapeutics Inc.'>PRVL</a>) initiated with Outperform rating and $25 (115% upside) price target at Wedbush. Initiated with Outperform rating at Cowen. Initiated with Overweight rating at Morgan Stanley.</li><li>Stoke Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/STOK' title='Stoke Therapeutics, Inc.'>STOK</a>) initiated with Overweight rating and $34 (26% upside) price target at JPMorgan. Initiated with Buy rating and $44 price target at Canaccord. Initiated with Outperform rating at Cowen.</li><li>Wave Life Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/WVE' title='Wave Life Sciences Ltd.'>WVE</a>) initiated with Market Perform rating at Cowen.</li><li>Cryoport (NASDAQ:<a href='https://seekingalpha.com/symbol/CYRX' title='Cryoport, Inc.'>CYRX</a>) initiated with Outperform rating and $24 (22% upside) price target at SVB Leerink.</li><li>Alkermes plc (NASDAQ:<a href='https://seekingalpha.com/symbol/ALKS' title='Alkermes plc'>ALKS</a>) upgraded to Neutral with a $27 (20% upside) price target at Goldman Sachs.</li><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) upgraded to Outperform with an $88 (33% upside) price target at Wells Fargo. Shares up <font color=\"green\">1% </font>premarket.</li><li>Agilent (NYSE:<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies, Inc.'>A</a>) downgraded to Equal Weight with a $78 (9% upside) price target at Barclays. Shares down <font color=\"red\">1% </font>premarket.</li><li>Mettler-Toledo (NYSE:<a href='https://seekingalpha.com/symbol/MTD' title='Mettler-Toledo International Inc.'>MTD</a>) downgraded to Underweight with a $680 (19% downside risk) price target at Barclays.</li><li>Quest Diagnostics (NYSE:<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a>) downgraded to Sell with an $85 (17% downside risk) at Goldman.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477623\" data-linked=\"Wells sees 33% upside in Gilead in premarket analyst action\" data-tweet=\"$AKRO $BCEL $PSNL - Wells sees 33% upside in Gilead in premarket analyst action https://seekingalpha.com/news/3477623-wells-sees-33-upside-in-gilead-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3477623-wells-sees-33-upside-in-gilead-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477620\" data-ts=\"1563190362\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAP\" target=\"_blank\">TAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477620-molson-coorsminus-2-after-two-notch-baml-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Molson Coors -2% after two-notch BAML cut</a></h4><ul> <li>Bank of America Merrill Lynch drops Molson Coors Brewing Company (NYSE:<a href='https://seekingalpha.com/symbol/TAP' title='Molson Coors Brewing Company'>TAP</a>) two notches to an Underperform rating from Buy.</li> <li>\"TAP has integrated the MillerCoors and Miller International acquisitions well from a cost and cash flow perspective while sales have lagged,\" notes BAML.</li> <li>\"We see heightened potential that TAP will need to increase spending to stabilize market share on core brands and accelerate investments in premium/'beyond' beer segments over the next year,\" warns the firm.</li>  <li>BAML's price objective goes all the way down to $50 from $70 to factor in lower EPS estimates for FY19 and FY20. The <a href=\"https://seekingalpha.com/symbol/TAP/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> is $65.94.</li> <li>Shares of TAP are <font color=\"red\">down 1.77%</font> premarket to $53.43.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477620\" data-linked=\"Molson Coors -2% after two-notch BAML cut\" data-tweet=\"$TAP - Molson Coors -2% after two-notch BAML cut https://seekingalpha.com/news/3477620-molson-coorsminus-2-after-two-notch-baml-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3477620-molson-coorsminus-2-after-two-notch-baml-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477617\" data-ts=\"1563189639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIR\" target=\"_blank\">CIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477617-crane-ends-pursuit-of-circor-cirminus-14\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crane ends pursuit of CIRCOR; CIR -14%</a></h4><ul><li>\"Due to failure of CIRCOR (NYSE:<a href='https://seekingalpha.com/symbol/CIR' title='CIRCOR International, Inc.'>CIR</a>) Board to engage in any discussions on behalf of CIRCOR shareholders,\" Crane (NYSE:<a href='https://seekingalpha.com/symbol/CR' title='Crane Co.'>CR</a>) <a href=\"https://seekingalpha.com/pr/17570700-crane-co-will-extend-offer-acquire-circor-international\" target=\"_blank\">says</a> it is \"ceasing its efforts to acquire CIRCOR and will not extend its $48 per share tender offer scheduled to expire on July 19, 2019.\"</li><li>CIR <font color=\"red\">-14.4%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3477617\" data-linked=\"Crane ends pursuit of CIRCOR; CIR -14%\" data-tweet=\"$CIR $CR - Crane ends pursuit of CIRCOR; CIR -14% https://seekingalpha.com/news/3477617-crane-ends-pursuit-of-circor-cirminus-14?source=tweet\" data-url=\"https://seekingalpha.com/news/3477617-crane-ends-pursuit-of-circor-cirminus-14\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477615\" data-ts=\"1563189557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPE\" target=\"_blank\">CPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477615-callon-petroleum-to-buy-carrizo-oil-gas-in-3_2b-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Callon Petroleum to buy Carrizo Oil &amp; Gas in $3.2B deal</a></h4><ul><li>Callon Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/CPE' title='Callon Petroleum Company'>CPE</a>) <a href=\"https://seekingalpha.com/pr/17570780-callon-acquire-carrizo-stock-transaction\" target=\"_blank\">agrees to acquire</a> Carrizo Oil &amp; Gas (NASDAQ:<a href='https://seekingalpha.com/symbol/CRZO' title='Carrizo Oil & Gas, Inc.'>CRZO</a>) in all-stock deal valued at $3.2B, saying the combination will create \"a premier Texas operator with an extensive inventory of core Permian and Eagle Ford locations that compete for capital on a full-cycle basis.\"</li><li>Under the deal terms, CRZO shareholders will receive 2.05 CPE shares for each share owned, representing $13.12 per CRZO share based on last Friday's closing stock price and an 18% premium to Carrizo's trailing 60-day volume weighted average price.</li><li>CPE says the combined company will have a ~200K net acre footprint in the Permian Basin and Eagle Ford Shale on a pro forma basis, including 90K-plus net acres in the Delaware Basin, and 2,500 total gross horizontal drilling locations; the companies produced a combined 102K boe/day in Q1 2019 (71% oil).</li><li>CRZO <font color=\"green\">+6.8%</font>, CPE <font color=\"red\">-12.5%</font> pre-market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477615\" data-linked=\"Callon Petroleum to buy Carrizo Oil &amp; Gas in $3.2B deal\" data-tweet=\"$CPE $CRZO - Callon Petroleum to buy Carrizo Oil &amp; Gas in $3.2B deal https://seekingalpha.com/news/3477615-callon-petroleum-to-buy-carrizo-oil-gas-in-3_2b-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3477615-callon-petroleum-to-buy-carrizo-oil-gas-in-3_2b-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>64&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477611\" data-ts=\"1563189123\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYMC\" target=\"_blank\">SYMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477611-symantecplus-1_7-on-broadcom-financing-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Symantec +1.7% on Broadcom financing report</a></h4><ul><li>Symantec (NASDAQ:<a href='https://seekingalpha.com/symbol/SYMC' title='Symantec Corporation'>SYMC</a>) <font color=\"green\">gains 1.7%</font> pre-market after the DealReporter says Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) has secured $23B in financing.</li><li>Last week, <a href=\"https://seekingalpha.com/news/3476806-broadcom-symantec-deal-come-monday-cnbc\" target=\"_blank\">CNBC sources</a> said Broadcom's acquisition of SYMC could be announced today.</li><li>The DealReporter report came out late Friday.</li><li>The $23B would reportedly include $21B for the purchase price and $2B for SYMC's convertible notes and other outstanding debt. The rest of Symantec's debt would be rolled over.</li><li>Post updated with more details from the report.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477611\" data-linked=\"Symantec +1.7% on Broadcom financing report\" data-tweet=\"$SYMC $NLOK $AVGO - Symantec +1.7% on Broadcom financing report https://seekingalpha.com/news/3477611-symantecplus-1_7-on-broadcom-financing-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3477611-symantecplus-1_7-on-broadcom-financing-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477610\" data-ts=\"1563189100\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477610-teva-down-5-premarket-on-morgan-stanley-downgrade-on-opioid-litigation-risk\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva down 5% premarket on Morgan Stanley downgrade on opioid litigation risk</a></h4><ul><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) slips <font color=\"red\">5%</font> premarket on average volume on the heels of a downgrade to Underweight with a $6 (35% downside risk) price target at Morgan Stanley &#40;MS&#41; citing its potential exposure from litigation associated with the U.S. opioid epidemic.</li><li>MS downgraded Endo International (NASDAQ:<a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a>) to Underweight with a $3 (27% downside risk) price target as well (shares down <font color=\"red\">5%</font> premarket on light volume).</li></ul><div class=\"tiny-share-widget\" data-id=\"3477610\" data-linked=\"Teva down 5% premarket on Morgan Stanley downgrade on opioid litigation risk\" data-tweet=\"$TEVA $ENDP - Teva down 5% premarket on Morgan Stanley downgrade on opioid litigation risk https://seekingalpha.com/news/3477610-teva-down-5-premarket-on-morgan-stanley-downgrade-on-opioid-litigation-risk?source=tweet\" data-url=\"https://seekingalpha.com/news/3477610-teva-down-5-premarket-on-morgan-stanley-downgrade-on-opioid-litigation-risk\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>146&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477609\" data-ts=\"1563189079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SDIPF\" target=\"_blank\">SDIPF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477609-sports-directminus-9-after-accounting-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sports Direct -9% after accounting delay</a></h4><ul> <li>Sports Direct International (<a href='https://seekingalpha.com/symbol/SDIPF' title='Sports Direct International plc'>OTCPK:SDIPF</a>) <a href=\"https://www.reuters.com/article/us-sports-direct-results/sports-direct-delays-results-as-house-of-fraser-deal-backfires-idUSKCN1UA0IC\" target=\"_blank\">delays</a> publishing its annual results due to complexities in integrating the House of Fashion business and \"uncertainty\" around the future trading performance of the business.</li> <li>The company anticipates filing the report sometime between July 26 and August 23.</li><li>Shares of Sports Direct are <font color=\"red\">down 9.42%</font> in London trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3477609\" data-linked=\"Sports Direct -9% after accounting delay\" data-tweet=\"$SDIPF - Sports Direct -9% after accounting delay https://seekingalpha.com/news/3477609-sports-directminus-9-after-accounting-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3477609-sports-directminus-9-after-accounting-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477606\" data-ts=\"1563188482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EAT\" target=\"_blank\">EAT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477606-brinker-internationalplus-1_4-after-jpmorgan-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brinker International +1.4% after JPMorgan upgrade</a></h4><ul> <li>JPMorgan lifts Brinker (NYSE:<a href='https://seekingalpha.com/symbol/EAT' title='Brinker International, Inc.'>EAT</a>) to an Overweight rating after having the restaurant stock was slotted at Neutral.</li> <li>The firm assigns a price target of $43 vs. the <a href=\"https://seekingalpha.com/symbol/EAT/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> of $45.84.</li> <li>Shares of Brinker are <font color=\"green\">up 1.42%</font> premarket vs. the 52-week trading range of $36.82 to $53.61.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3477606\" data-linked=\"Brinker International +1.4% after JPMorgan upgrade\" data-tweet=\"$EAT - Brinker International +1.4% after JPMorgan upgrade https://seekingalpha.com/news/3477606-brinker-internationalplus-1_4-after-jpmorgan-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3477606-brinker-internationalplus-1_4-after-jpmorgan-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477600\" data-ts=\"1563187847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAPR\" target=\"_blank\">CAPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477600-capricor-up-45-premarket-on-positive-capminus-1002-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Capricor up 45% premarket on positive CAP-1002 data</a></h4><ul><li>Thinly traded nano cap Capricor Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CAPR' title='Capricor Therapeutics, Inc.'>CAPR</a>) is up <font color=\"green\">45%</font> premarket on modest volume in response to its <a href=\"https://seekingalpha.com/pr/17570682-capricor-therapeutics-announces-positive-results-interim-analysis-hopeminus-2-trial-treat\" target=\"_blank\">announcement </a>of positive six-month data from its Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03406780?term=capricor&amp;rank=5\" target=\"_blank\">HOPE-2</a>, evaluating lead candidate CAP-1002 in steroid-treated boys and young men with advanced stages of Duchenne muscular dystrophy &#40;DMD&#41;.</li><li>Interim data were generated from 17 subjects (10 placebo/7 treated) at month 3 and 12 subjects (6 placebo/6 treated) at month 6. About 80% of the participants were unable to walk.</li><li>Improvements in tip to tip pinch strength and grip strength were noted at month 6 compared to declines in the control group. Upper limb function declined slightly, but the decline was less than control. Upper limb function improved slightly at month 3 but declined to month 6, however.</li><li>A measure of diaphragm strength called inspiratory flow reserve improved at month 3 but the results at month 6 are not provided.</li><li>Positive trends in cardiac muscle function were also noted.</li><li>On the safety front, only one serious adverse event was reported subsequent to the institution of a premedication strategy with intravenous steroids and antihistamines (in late 2018, the company placed a voluntary hold on dosing after two patients experienced severe immune reactions).</li><li>Management will host a conference call this morning at 8:00 am ET to discuss the results.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477600\" data-linked=\"Capricor up 45% premarket on positive CAP-1002 data\" data-tweet=\"$CAPR - Capricor up 45% premarket on positive CAP-1002 data https://seekingalpha.com/news/3477600-capricor-up-45-premarket-on-positive-capminus-1002-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3477600-capricor-up-45-premarket-on-positive-capminus-1002-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3477596\" data-ts=\"1563186287\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLPG\" target=\"_blank\">GLPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3477596-galapagos-up-16-premarket-on-gilead-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galapagos up 16% premarket on Gilead deal</a></h4><ul><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos NV'>GLPG</a>) is up <font color=\"green\">16%</font> premarket on average volume in response to the <a href=\"https://seekingalpha.com/news/3477580-gilead-boost-galapagos-stake-5_1b-deal\" target=\"_blank\">news </a>that Gilead Sciences will up its stake in the company to 22% coupled with a 10-year R&amp;D agreement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3477596\" data-linked=\"Galapagos up 16% premarket on Gilead deal\" data-tweet=\"$GLPG - Galapagos up 16% premarket on Gilead deal https://seekingalpha.com/news/3477596-galapagos-up-16-premarket-on-gilead-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3477596-galapagos-up-16-premarket-on-gilead-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}